PERSONAL HISTORY Work Pfleger Liver Institute Suite 214

Updated 4/2020

Saab 1

CURRICULUM VITAE

Saab, Sammy, MD, MPH

PERSONAL HISTORY

Work Pfleger Liver Institute

200 UCLA Medical Plaza

Suite 214

Los Angeles, CA 90095-7302

Tel: 310-206-6705, Fax: 310-206-4197

[email protected]

EDUCATION

1985 - 1989 Bachelor of Science ~ Psychobiology

University of California at Los Angeles

1989 - 1993 Doctor of Medicine


1993 - 1996 Internship and Residency ~ Internal Medicine

University of California at San Diego, Medical Center

1996 - 1997 Chief Medical Resident


1997 - 2000 Fellowship ~ Gastroenterology/Hepatology

University of California at Los Angeles, Center for Health Sciences

1999 - 2001 Master of Public Health ~ Epidemiology


LICENSURE

State, Certificate Number CA, GO80181

BOARD CERTIFICATION

Eligible American Board of Internal Medicine

Active Gastroenterology

Active Drug Enforcement Agency

Active Certification in Transplant Hepatology

PROFESSIONAL EXPERIENCE

Current

2012 - present Professor of Clinical Medicine

Division of Digestive Diseases, Department of Internal Medicine and

Dumont-UCLA Liver Transplantation, Department of Surgery


mailto:[email protected]

Saab 2

Previous

1995 - 1997 Volunteer Physician

Saint Vincent DePaul Homeless Shelter, San Diego, California

1996 - 1997 Clinical Instructor, Department of Internal Medicine


2000 - 2002 Clinical Instructor

Division of Digestive Diseases, Department of Internal Medicine


2001 - 2002 Clinical Instructor



2002 - 2006 Assistant Clinical Professor (Comp)




2006 - 2008 Associate Clinical Professor (Comp)




2007 - present Head, Outcomes Research in Hepatology

Pfleger Liver Institute, University of California at Los Angeles

2008 - 2012 Associate Professor of Clinical Medicine




2010 - present Adjunct Professor

School of Nursing, University of California at Los Angeles

2012 - present Professor of Clinical Medicine (X)




2020 Medical Director, Adult Liver Transplant, Dumont-UCLA Liver

Transplantation, Department of Surgery, University of California at Los

Angeles, Center for Health Sciences

2020 Chief, Hepatology, Department of Internal Medicine and Dumont-UCLA

Liver Transplantation, Department of Surgery University of California at

Los Angeles, Center for Health Sciences

Saab 3

2020 Director, Pfleger Liver Institute, University of California at Los Angeles,

Center for Health Sciences

PROFESSIONAL AFFILIATIONS

American Association for the Study of Liver Disease

American College of Gastroenterology

American Gastroenterological Association

American Society of Transplantation

Italian Society of Surgical Research- Societa' Italiana di Ricerche in

Chirurgia, honorary member

PROFESSIONAL ACTIVITIES

Local

2001 - present American Liver Foundation, Los Angeles Chapter

Medical Advisory Committee

2001 - 2014 University of California Los Angeles, Department of Medicine

Residency Selection Committee

2001 - present University of California Los Angeles, Department of Surgery

Multidisciplinary Patient Selection Committee for Liver Transplantation

2005 - present University of California Los Angeles, Division of Transplantation

Liver Transplant Executive Committee

2005 - 2014 Ventura County/West Valley Chapter of TRIO

Medical Advisory Committee

2006 - 2014 University of California Los Angeles, Department of Medicine

Morbidity and Mortality Committee

National/International

2004 – 2007 Educational Committee

American Association for the Study of Liver Diseases

2004 - 2007 Liver and Intestines Committee


2006 - 2008 Practice Guidelines Committee


2006 Review Committee for Internal Medicine, Pre-reviewer for Liver

Transplantation, Accreditation Council for Graduate Medical Education

2005 International Liver Transplantation Society

Abstract chair, Recurrent Disease and Infectious Disease

2008 - 2014 Board of Appeals Panel for Transplant Hepatology

Accreditation Council for Graduate Medical Education

2008 - 2017 Abstract Reviewer - Health Services Research: Health Care

Delivery/Quality/Effectiveness - Access to Care; Economics of Care.


2010 Abstract Reviewer – Recurrent Diseases. American Transplant Congress

2011 - 2014 Journals Publications Committee. American Association for the Study of

Liver Diseases

Saab 4

2018 Abstract Review Chair Reviewer - Health Services Research: Health Care



2019 Abstract Review Chair Reviewer - Health Services Research: Health Care


American Association for the Study of Liver Diseases:

Saab 5

HONORS/AWARDS

1990 Pacific Basin Scholarship

1991 Psychiatry Summer Research Fellowship

1993 Merck Book Award

1999 AGA/Wyeth-Ayerst Resident and Fellows Reporter Award

1999 Gastroenterology Fellow of the Year, University of California Los

Angeles

2000 Cochrane Hepato-Biliary Group Award for Systematic Review

2000 American Society of Transplantation Travel Award

2000 AASLD/Schering Advanced Hepatology Fellowship Award

2000 American College of Gastroenterology Clinical Research Award

2005 Outstanding Reviewer Award, American Journal of Gastroenterology

2006 Outstanding Reviewer Award, American Journal of Gastroenterology

2008 Fellow, American Gastroenterology Association

2008 Distinguished Achievement Award, Division of Digestive Diseases

2009 Visiting Lecturer, Kansas University Medical Center, Kansas City

2009 Visiting Lecturer, John Hopkins Hospital, Baltimore

2010 Visiting Lecturer, Beth-Israel Deaconess Medical Center, Boston

2010 Visiting Lecturer, Brooke Army Medical Center, San Antonio, Texas

2010 Visiting Lecturer, Albert Einstein Medical Center, Philadelphia,

Pennsylvania

2013 Visiting Lecturer, Carolinas Healthcare Medical Center, Charlotte, North

Carolina

2014 Fellow, American Association for the Study of Liver Diseases

2016 Visiting Lecturer, Medical College of Wisconsin, Milwaukee, Wisconsin

2016 Outstanding Contribution Award. Journal of Clinical and Translational

Hepatology

Saab 6

2017 Outstanding Contribution Award. Journal of Clinical and Translational

Hepatology

2019 Visiting Lecturer, UCSF – Fresno Medical Center, Fresno, California

JOURNAL REFERREE ACTIVITIES

Associate Editor Digestive Medicine Research (DMR)

Journal of Clinical and Translational Hepatology

Journal of Clinical Gastroenterology

Assistant Editor American Journal of Gastroenterology

Liver International

World Journal of Gastroenterology

Reviewer

American Journal of Gastroenterology

American Journal of Medicine

Clinical Transplantation

Gastroenterology

Gastroenterology & Hepatology

Hepatology

Liver Transplantation

RESEARCH MENTORING

Name Year

High School

Teddy Alpers 2013

Ernesto Sernas 2014

Caterina Kachadoorian 2014

Naadir Jamal 2014 - 2015

Zoha Jamal 2015

Tori Alper 2015, 2017

Alexander Farid 2015 - 2016

Elena Saab 2015 - 2017

Alex Lee 2017

College Students

Pari Pruthi 2013 - 2014

Crystal Wu 2013 - 2016

Tiffany Wong 2013 - 2016

Melissa Jimenez 2014 - 2015

Theodore Alper 2014 - 2015

Matthew Viramontes 2015 - 2017

Caterina Kachadoorian 2016 - 2017

Saab 7

UCLA Medical Students

Amanda Chi 2007 - 2008

Calvin Nguyen 2008 - 2009

Benjamin Waterman 2009 - 2010

Kelvin Nguyen 2010 - 2011

Michael Choi 2011 - 2012

Jessica Ferguson 2012 - 2014

Edwin Lee 2014

Edward Chang 2014

Peter Konyn 2016

Philip Chen 2017

Emily Truong 2017

Dana Song 2018

UCLA Medical Residents

Robert Lin 2000 - 2002

Albert Chang 2002 - 2003

Denise Kalmaz 2003 - 2004

Shannon Lewis 2003 - 2004

Dan Cho 2003 - 2005

Stephen Nguyen 2005 - 2006

Christine Wiese 2006 - 2007

Mamie Dong 2006 - 2008

Maggie Ham 2008 - 2009

Vickie Wu 2008 - 2009

Bijal Surti 2008 - 2009

Melina Yeganh 2008 - 2009

Hiliary Bownik 2008 - 2010

Vivian Ng 2008 - 2011

Michael McTigue 2009 - 2010

Shirena Desai 2009 - 2012

Michael Chang 2010 - 2012

Kareem Sassi 2011 - 2012

Kali Zhou 2012 - 2014

Adam Greenberg 2014 - 2015

Sara Park 2015 – 2015. Recipient of AASLD Emerging Liver Scholar

Resident Travel Award

Elizabeth (Lizzie) Aby 2015 – 2015. Recipient of AASLD Emerging Liver Scholar

Resident Travel Award

Harman Rahal 2018 - present

Nathan Kim 2019 - present

Eric Wu 2019 - present

Saab 8

UCLA Gastroenterology Fellows

Shibhan Weston 2002 - 2003

Jose Nieto 2004 - 2006

Andrew Kim 2006 - 2007

Lenna Martyak 2007 - 2008

Carmen Landaverde 2007 - 2009

Jennifer Tan 2007 - 2009

Justin Reynolds 2012 - 2013

Vivian Ng 2012 - 2013

Gina Choi 2013 - 2014

Victoria Sheen 2014

Tyrlaee Goo 2014 - 2015

Kelvin Nguyen 2016 - 2018

Ani Kardashian 2017-2018

Adam Winters 2019-2020

Medical Residents at outside Institutions

Vincent De Rosa 2002 - 2003 West VA Medical Center

Jose Nieto 2002 - 2004 West VA Medical Center

Victor Wang 2003 - 2004 West VA Medical Center

Andrew Kim 2004 - 2005 West VA Medical Center

Alex Shpaner 2004 - 2006 West VA Medical Center

Carmen Landaverde 2005 - 2006 Olive-View Medical Center

Mina Oh 2006 - 2007 Cedars-Sinai Medical Center

J Carlos Hernandez 2007 - 2008 Harbor-UCLA Medicine Resident

Douglas Hunt 2007 - 2009 Harbor-UCLA Medicine Resident

Divya Mallam 2013 Harbor - UCLA Medicine Resident

Eshan Akhtar 2014 Harbor - UCLA Medicine Resident

Justin Rheem 2014 - 2017 Harbor - UCLA Medicine Resident

Duminda Suraweera 2014 - 2017 Olive-View Medical Center

Long Le 2017 - 2019 Olive-View Medical Center

UCLA Medical Student Courses

First year students

Liver Detoxification of Alcohol and Ammonia

Second year students

Jaundice and Cholestasis

Spectrum of Fatty Liver Disorders

Drugs and the Liver

Medical–Surgical GI Conference

Saab 9

RESEARCH FUNDING

Current

Principle Investigator: IDN-

6556-17: A Multicenter, Randomized, Double-Blind, Placebo-Controlled

Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with

Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis

(Conatus Pharmaceuticals)

Principal Investigator, A Multicenter, Randomized, Double-blind,

Placebo-Controlled Trial of Emricasan (IDN-6556), an Oral Caspase

Inhibitor, in Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis

(Conatus Pharmaceuticals)

Co-Investigator, A Phase II Randomized Multicenter Placebo-Controlled

Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic

Liver Transplant (OLT) Recipients with Hepatocellular Carcinoma (HCC)

(Bayer Pharmaceuticals)

Previous

Principal Investigator, A Multicenter, Double-Blind, Randomized Trial of

IDN-6556 in Subjects Who had Hepatitis C Virus (HCV) Reinfection and

Liver Fibrosis or Cirrhosis Following Orthotopic Liver Transplantation for

Chronic HCV Infection and Who Subsequently Achieved a Sustained

Virologic Response Following anti-HCV Therapy (Conatus

Pharmaceuticals)

Principal Investigator, A randomized, open-label, multicenter, efficacy

and safety study of PEGASYS® for the treatment of hepatitis C virus

infection administered to patients six to sixty months post liver

transplantation (Roche Pharmaceuticals)

Co-Investigator, Fungal Prophylaxis with Liposomal Amphotericin B or

Amphotericin B Lipid Complex in patients undergoing liver

transplantation (Fujisawa Healthcare/Astellas)

Co-Investigator, Adult to Adult Living Liver Transplantation (U01-

National Institute of Health)

Investigator, A Double-Blind, Randomized, Placebo-Controlled Multi-

Center, Phase II Parallel Dose-Ranging study to Assess the Antifibrotic

Activity of GI262570 in Chronic Hepatitis C Subjects with Hepatic

Fibrosis who Have Failed Prior Antiviral Therapy (FBX 104114) (Glaxo).

Co-Investigator, A prospective, open-label, multi-center, randomized trial

of the efficacy and safety of a long-term calcineurin inhibitor free

maintenance regimen with Mycophenolate Mofetil and sirolimus in

Saab 10

recipients of an orthotopic liver transplant. Protocol Number: ML18423

(Roche Pharmaceuticals)

Principal Investigator, A Phase 3, Safety and Efficacy Study of Boceprevir

in Previously Untreated Subjects with Chronic Hepatitis C Genotype 1

(Schering Plough)

Co-Investigator, Models for Liver Transplantation Outcomes (R01-

National Institute of Health

Principal Investigator, Phase 3 Safety and Efficacy Study of

Erythropoietin Use During Treatment of Subjects with Chronic Hepatitis

C with Boceprevir Peginterferon Alfa 2B, and Ribavirin (Schering

Plough)

Investigator, Interferon-induced Graft Function after Liver

Transplantation: Multicenter Case-Control Study (Northwestern

University/Schering Corporation)

Principal Investigator

A Multi-Center, Randomized, Open Label, Controlled Study to Compare

the Sustained Virological Response During Treatment with Neoral or

Tacrolimus in Maintenance Liver Transplant Recipients Treated with

Pegylated Interferon and Ribavirin for Recurrent Hepatitis C (Novartis

Pharmaceuticals)

Investigator

PROTECT-Pegylated Interferon alfa-2b and Ribavirin After Orthotopic

Liver Transplantation: Efficacy and Safety in Hepatitis C Recurrence

Therapy (P04590) (Schering-Plough)

Co-Investigator

A randomized, open-label, multicenter, efficacy and safety study of

PEGASYS® and Copegus as a against hepatitis C virus infection

recurrence after liver transplantation (Roche Pharmaceuticals)

Co-Investigator

A prospective, randomized, open label 26 week study of the efficacy and

safety of converting post-kidney and liver transplant patients with

tacrolimus-associated abnormal glucose metabolism to Neoral with C-2h

monitoring. (Novartis Pharmaceuticals)


A Phase II, Multicenter, Randomized, Open-Label, Dose-Ranging

Parallel Group Study to Compare the Anti-Viral Effects,

Pharmacokinetics, and Safety of HepeX-B as Compared to Hepatitis B

Immune Globulin in Patients Who Have Received Hepatic Allografts

for Hepatitis Virus Infection. (XTL Biopharmaceuticals, Inc)

Saab 11

Co-Investigator

Comparison of PEG Interferon alfa-2b plus Ribavirin Given as a Fixed

dose or on a weight optimized basis for treatment of chronic hepatitis C in

previously untreated adult subjects (Schering Pharmaceuticals)

Co-Investigator

A randomized, open-label, multicenter, efficacy and safety study of

PEGASYS® as a prophylaxis against hepatitis C virus infection

recurrence after liver transplantation (Roche Pharmaceuticals)


Epidemiology of hepatitis C in the hemodialysis community. Designed

decision analysis models for hepatitis C screening in hemodialysis patients

(AASLD/Schering Fellowship Award)

Post-Doctoral Fellow

Study of receptor mediators of hepatic stellate cell contraction (National

Institute of Health Training Grant)

LECTURES AND PRESENTATIONS

National

1991 Seminar ~ Misidentification, Biology and Culture

University of California at Los Angeles, Neuropsychiatric Institute

Los Angeles, California

1996 Department of Medicine Grand Rounds ~ AIDS and Ascites


San Diego, California

1998 VA/UCLA CURE Annual Clinical Research Meeting ~ Risk Factors for

the Development of Hepatocellular Carcinoma

West Los Angeles VA Medical Center, Los Angeles, California

1999 Division of Gastroenterology Grand Rounds ~ Hepatitis A Cost-Preferred

Vaccine Strategies


1999 Current Topics in Gastroenterology ~ Vaccination Strategies for

Hepatitis A Infection

Nassau, Bahamas

1999 VA/UCLA CURE Annual Research Meeting ~ The Role of

Aminotransferases to Screen for Viral Hepatitis in Hemodialysis Patients


2000 Southern California Society of Gastroenterology ~Update on Hepatitis C

Treatment

Santa Barbara, California

2001 AIDS Project Advocacy Annual Seminar ~ Update on Hepatitis C

AIDS Project Advocacy, Los Angeles, California

2001 Pathophysiology of Diseases ~ Cirrhosis

Saab 12

Second year medical student lecture, UCLA School of Medicine

2002 Department of Pharmacy Grand Rounds ~ Update on Hepatitis C:

Epidemiology, Natural History, and Treatment


2002 Pathophysiology of Diseases ~ Cirrhosis

Second year medical student lecture, UCLA School of Medicine

2002 Department of Medicine Grand Rounds ~ Update on Hepatitis C

University of California Los Angeles, Medical Center


2002 Department of Medicine Grand Rounds ~ Hepatitis C Diagnosis and

Management

Good Samaritan Hospital, Los Angeles, California

2002 Department of Pathology Grand Rounds ~ Natural History, Epidemiology,

and Diagnosis of Hepatitis C



2003 Update on Hepatitis C ~ Natural History and Diagnosis

Southern California Society of Gastroenterology

2003 Hepatitis B ~ Evaluation and Management

Arthur Ashe Student Health and Wellness Center


2003 Department of Medicine Grand Rounds ~ Liver Transplantation in the era

of MELD



2003 Hepatitis C ~ Current Status

Arthur Ashe Student Health and Wellness Center


2003 Division of Nephrology Grand Rounds ~ The Impact of Hepatitis C on

Patients with Kidney Disease


2004 Hepatitis C ~ Evaluation and Management

Hemophilia Center

Orthopedics Hospital, Los Angeles, Californi

2004

2004 Update on Hepatitis C and Liver Transplantation

Southern California Society of Gastroenterology

2004 Liver Cirrhosis: Current Management

Kaiser Permanente, Panorama City

2004 UCLA Update in Gastroenterology and Hepatology ~ Chronic Hepatitis

with Negative Viral Serologies

Century City, California

2004 Department of Pathology and Laboratory Medicine ~ Chronic Viral

Hepatitis



2004 Division of Nephrology Grand Rounds ~ Current Concepts of Hepatitis C

in Patients with Kidney Disease

Saab 13


2004 Hepatitis C – Update in treatment and diagnosis

Chronic Liver Diseases and Hepatocellular Carcinoma: State-of-the-Art

Management. David Geffen School of Medicine at UCLA

2004 Department of Medicine Grand Rounds ~ Expanding Hepatitis C Care:

Managing Side Effects and Comorbidities.

VA Pacific Islands Health Care System, Honolulu, Hawaii

2004 State-of-the-Art Controversies: Steroid withdrawal vs No steroid

withdrawal for Hepatitis C.

Third International Congress on Immunosuppression

San Diego, California

2005 UCLA Update in Gastroenterology and Hepatology ~ Understanding and

Treating Non-viral Causes of Chronic Hepatitis

Beverly Hills, California

2005 Department of Medicine Grand Rounds ~ Treating Hepatitis C and HIV

Coinfection

Cottage Hospital, Santa Barbara, California

2005 American Transplant Congress Annual Scientific Meeting – Sunrise

Symposia on Improving Patient Outcomes Screening ~ Patients with

Cirrhosis (Chair and Speaker)

Seattle, Washington

2005 Kaiser Permanente National Gastroenterology Conference ~ Chronic

Hepatitis B: Evolving Treatment Strategies

Las Vegas, Nevada

2005 Emerging Treatments for Liver and Complex ~ Hepatitis B virus:

Treatment all Patients Now vs Delay Treatment

San Francisco, California

2005 Treatment of HIV/HCV Coinfection ~ Kaiser Permanente

Hollywood, California

2005 Treating Hepatitis - Maximizing Response and Minimizing injury (CME

activity) Los Angeles, California

2005 Treatment of HIV/HCV Coinfection ~ A Hepatologist Perspective (CME

activity) Santa Monica, California

2005 Southern California Society of Gastroenterology ~ Update on Hepatitis C

Laguna Beach, California

2005 Department of Medicine Grand Rounds ~- Current and Upcoming

Treatments (CME activity) and Treatment of Hepatitis B and C (CME

activity) ~ Doctor’s Hospital Medical Center, Montclair, California

2006 UCLA Gastroenterology Symposium ~ Screening for HCC and Biliary

Cancer in High-Risk Patients: What Should we be Doing? (CME activity)

~ Beverly Hills, California

2006 Hepatitis B and Infectious Disease Training Program ~ Review of Viral

Hepatitis, Discovery of HBV and Natural History (CME activity) ~

Beverly Hills, California

2006 Hepatitis B and Infectious Disease Training Program ~ Treatment

Guidelines (CME activity) ~ Beverly Hills, California

Saab 14

2006 UCLA State-of-the-Art Treatment for Diseases of the Liver ~ Improved

Efficacy of Hepatitis C Treatment, with Current and Future Therapies

(CME activity) ~ Costa Mesa, California

2006 UCLA Case Manager Update 2006 ~ Update on Hepatitis C (CME

activity) ~ Los Angeles, California

2006 Digestive Disease Week Combined Clinical Symposium ~ Care of the

Liver Transplant Patient in a Non-Transplant Center ~ Recurrent Disease

in Liver Transplant Recipients (CME activity) ~ Los Angeles, California

2007 Department of Medicine Grand Rounds ~ Chronic Hepatitis C Infection ~

Charles Drew University, Martin Luther King, Jr Hospital, Los Angeles,

California

2007 Department of Medicine UCLA Board Review Course ~ Viral Hepatitis

and other Liver Diseases ~ Center for Health Services, Los Angeles,

California

2007 Hepatitis C and Infectious Disease Training Program ~ Treatment

Guidelines (CME activity) ~ Los Angeles, California

2007 Common Causes of Hepatitis: Evaluation and Management (CME

activity) ~ Antelope Valley Hospital ~ Lancaster, California

2007 Department of Medicine Grand Rounds ~ Update in Chronic Hepatitis C

Infection: Current and Future Infections ~ Harbor-UCLA Medical Center,

Torrance, Los Angeles, California

2007 Hepatitis B in the Asian-American Community (CME activity)

University of the East Ramon Magsaysay Medical Alumni Association,

Buena Park, California

2007 Optimal Treatment in Hepatitis C (CME activity)

www.hcvcme.tv

2007 Hepatitis B and Infectious Disease Training Program ~ Review of Viral

Hepatitis, Discovery of Hepatitis B and Natural History (CME activity) ~

San Gabriel, California

2007 Division of Nephrology Grand Rounds ~ Hepatitis C in Renal Failure:

Impact and Treatment ~ Harbor-UCLA Medical Center, Torrance, Los

Angeles, California

2007 Division of Liver Transplantation Grand Rounds ~ To Treat or Not to

Treat Hepatitis C Cirrhosis ~ University of California Los Angeles,

Medical Center Los Angeles, California

2007 Department of Medicine Grand Rounds ~ Hepatitis B – Update in

Diagnosis and Treatment Guidelines (CME activity)~ Tuscon Medical

Center, Tuscon, Arizona

2007 Department of Medicine Grand Rounds ~ Hepatitis C – Current Strategies

in Diagnosis and Treatments (CME activity)~ Billings Medical Center,

Billings, Montana

2007 Department of Medicine Grand Rounds ~ Management and Treatment of

Chronic Hepatitis C. (CME activity)~ Huntington Memorial Hospital,

Pasadena, Montana

2007 Hepatitis C and Infectious Disease Training Program ~ Review of Viral

Hepatitis, Discovery of Hepatitis C and Natural History (CME activity) ~


2007 Advances in Transplantation ~Changing the Natural History of

Saab 15

Hepatitis C in Liver Transplant Recipients (CME activity)~ San Diego,

California

2007 Advances in Transplantation ~Strategies in Hepatitis B Therapy in Liver

Transplantation (CME activity)~ San Diego, California

2007 Department of Medicine Grand Rounds ~ Fatty Liver –Diagnosis and

Treatment (CME activity)~ Providence Medical Center, Mission Hills,

California

2007 Third Annual University of California Irvine Hepatology Symposium

2007 ~ Treatment of Hepatitis C Infections in Special Populations (CME

activity) ~ Palm Springs, California

2007 General Hepatology Update ~ American Association for the Study of

Liver Diseases ~ Moderator ~ Boston, Massachusetts

2007 Hepatitis B: Diagnosis and Management ~ Asche Arthur Student Health

and Wellness Center ,UCLA, Los Angeles, California

2007 Hepatocellular Carcinoma: Multi-Disciplinary Management 2007 (CME

activity) ~ Chemotherapy and Chemo Prevention of HCC ~ Session Chair

~ Los Angeles, California

2008 Strategies in Hepatitis B Management – Pre and Post Liver

Transplantation ~ Liver Institute, Methodist Dallas Medical Center ~

Dallas, Texas

2008 Department of Medicine Grand Rounds ~ Management of Hepatitis B

(CME activity)~ St Joseph Hospital, Orange, California

2008 Department of Medicine Grand Rounds ~ Current Strategies in the

Diagnosis and Treatment of Chronic Hepatitis B Infection (CME

activity)~ Providence Little Company of Mary Hospital, California

2008 Refractory Ascites Clinical Symposium for the American Association for

the Study of Liver Diseases ~ Clinical Impact of Refractory Ascites ~

Digestive Disease Week, San Diego, California

2008 Hepatitis B and Infectious Disease Training Program ~ Review of

Resistance and Treatment Guidelines (CME activity) ~ San Gabriel,

California

2008 Department of Medicine Grand Rounds ~ Current and Future Trends in

Hepatitis C Treatment (CME activity) ~ Harbor-UCLA Medical Center,

Torrance, Los Angeles, California

2008 Managing Adverse Effects with Hepatitis C Antiviral Therapy (CME

activity). www.hcvcme.tv

2008 Department of Surgery Grand Rounds ~ Immunosuppressant Strategies in

Liver Transplant Recipients ~ Los Angeles Kaiser Permanente, Los

Angeles, California

2008 Department of Anesthesiology Grand Rounds ~ Hepatitis C Viral

Infection: Diagnosis and Management Strategies (CME activity) ~

Harbor-UCLA Medical Center, Torrance, Los Angeles, California

2008 Thomas Street Health Center ~ Managing Treatments for Hepatitis C

Nonresponders and Relapsers (CME activity) ~ Houston, Texas

2008 Department of Medicine Grand Rounds ~ Management of Cirrhosis, and

its Complications (CME activity) ~ Providence Little Company of Mary

Hospital, California

Saab 16

2008 Division of Gastroenterology Grand Rounds ~ Treatment of Hepatitis C:

Before and After Transplantation ~ University of Pennsylvania,

Philadelphia, Pennsylvania

2008 Second Annual UCLA Liver Diseases Symposium ~ Management of

Cirrhosis, and its Complications (CME activity) ~ University of California

Los Angeles, Pasadena, California

2008 Southern California Society of Gastroenterology ~ Hepatitis C - Current

Treatments (CME activity). Laguna Beach, California

2009 Emerging Medical Therapies for Hepatitis C ~UCLA Liver

Transplantation Scientific Symposium, Los Angeles, California

2009 Controversies in Treating Hepatitis C before and after Liver

Transplantation ~ LifeLink HealthCare Institute, Tampa, Florida

2009 Pacific Hospital of Long Beach ~ Chronic Viral Hepatitis

Long Beach, California

2009 Health Effects of Alcohol: What your Patients and Clients need to know ~

Viral Hepatitis, Alcohol and liver Transplantation (CE activity) Alhambra,

California

2009 Department of Medicine Grand Rounds ~ Complications of Cirrhosis and

Hepatocellular Carcinoma (CME activity) ~ John F Kennedy Memorial

Hospital, Indio, California

2009 American Transplant Congress Annual Meeting ~ Quality of Life in Liver

Transplant Recipients ~ Boston, Massachusetts

2009 Department of Medicine ~ Management Strategies for the Hepatitis C

Treatment Failures ~ Winthrop University Hospital, New York, New York

2009 Outpatient Management of GI/Hepatology Diseases ~Update on Post-

Liver Transplant Immunosuppressive Management ~ University of

California Irvine Healthcare ~ Orange, California

2009 Department of Medicine Grand Rounds ~ New Treatment Options and

Strategies for Hepatitis C (CME activity) ~ Parkview Community Medical

Center, Riverside, California

2009 Hepatitis C ~ Training Program and Treatment Update (CME activity) ~


2009 Assessing Recent Advancements in the Management of ITP and

Thrombocytopenia Secondary to Other Disorders ~ Managing

Thrombocytopenia in Patients with Chronic Liver Disease (CME activity)

~ Los Angeles, California

2009 Department of Medicine Grand Rounds ~ Diagnosis, Clinical Implications

and Treatment of Hepatitis C (CME activity) ~ University of California

Los Angeles ~ Los Angeles, California

2009 Prevention and Management of Esophageal Variceal Hemorrhage. ~

Meet-the Professor Luncheon ~ American Association for the Study of

Liver Diseases ~ Boston, Massachusetts

2009 Third Annual UCLA Liver Diseases Symposium ~ Current and Future

Treatment of Hepatitis C~ (CME activity) ~ University of California Los

Angeles, Pasadena, California

2009 53rd Annual Raymond M. Kay, MD Internal Medicine Symposium ~

Evaluation of Liver Enzymes (CME activity) ~ Kaiser Permanente,

Rancho Mirage, California

Saab 17

2009 Treatment of Unresectable Hepatocellular Carcinoma ~New Mexico

Cancer Center~ Albuquerque, New Mexico

2009 Evaluation of Patients with Unresectable Hepatocellular Carcinoma ~

University of Texas Memorial Herman ~ Houston, Texas

2009 Strategies in Patients with Hepatocellular Carcinoma~ Liver Institute at

Methodist Dallas Medical Center ~ Dallas, Texas

2009 Division of Gastrointestinal Grand Rounds ~ Hepatocellular Carcinoma:

Implications, Diagnosis and Management (CME activity) ~ University of

Texas Southwestern Medical Center ~ Dallas, Texas

2009 Southern California Society of Gastroenterology ~ AASLD 2009 Update

on Non-genotype 1 Patients (CME activity). Dana Point, California

2009 Inland GI Midlevel Network ~ Update on AASLD 2009 ~ Riverside,

California

2009 Medical Grand Rounds ~ New Strategies in Hepatitis C Therapy ~ Hemet

Valley Medical Center ~ Hemet, California

2010 Sierra Sacramento Valley Medical Society~ What the Liver can do for

You (CME activity ~ Sacramento, California

2010 Medical Grand Rounds ~ Management of Cirrhosis and Hepatocellular

Carcinoma (CME activity) ~ Valley Presbyterian Hospital, Van Nuys,

California

2010 Medical Grand Rounds Grand Rounds ~ Fatty Liver ~ A Sleeping Giant

(CME activity) ~ Overlake Hospital Medical Center, Bellevue,

Washington

2010 Medical Grand Rounds ~Hepatic Lesions ~ Incidental and Non-Incidental

Lesions (CME activity) ~ Providence Holy Cross Medical Center, Mission

Hills, California

2010 Arapahoe Gastroenterology Pow-Wow Conference ~ Approach to the

Patient with Hepatitis B. Littleton, Colorado

2010 Evaluation in Chronic Hepatitis C (CME activity) ~ Henderson County

Medical Society, Athens, Texas

2010 Management of Side Effects of Therapy ~Complications of Hepatitis C

(CME activity) ~Audio-Digest Gastroenterology.

2010 Hepatitis B Diagnosis and Treatment (CME activity) ~ California

Association Nurse Practitioners ~ West LA Chapter, Beverly Hills,

California

2010 Hepatitis C ~ Training Program and Treatment Update (CME activity) ~


2010 11th Annual International Hot Topics in Liver Disease Conference

~Treating Hepatocellular Carcinoma (CME activity)~Houston, Texas

2010 Pri-Med ~Chronic Hepatitis B Virus Infection: Screening and Linkage to

Care in the Asian Community (CME activity) ~ Chicago, Illinois

2010 Hepatitis C in Special Populations (CME activity) ~ Asian Physician

Group ~ Fountain Valley, California

2010 Hepatitis B ~ AASLD 2010 Update (CME activity) ~ Texas Gulf Coast

Gastroenterological Society ~ Houston, Texas

2010 Hepatitis C: Clinical Impact, Natural History, and Treatment ~ Hepatitis C

Task Force for Los Angeles ~ Los Angeles, California

Saab 18

2010 Fourth Annual UCLA Liver Diseases Symposium ~ Current and Future

Treatment of Hepatitis C~ (CME activity)~ University of California Los


2010 Southern California Society of Gastroenterology ~ Hepatitis B Resistance

and Safety Concerns -(CME activity). Dana Point, California

2010 Hepatitis Symposium ~ Hepatocellular Carcinioma ~ Screening,

Diagnosis, and Management. -(CME activity). Honolulu, Hawai‘i

2010 Chronic Hepatitis C Virus Infection: Screening and Linkage to Care -

(CME activity). Hilo Medical Center Grand Rounds, Hilo, Hawai‘i.

2011 Association of Black Woman Physicians. Best Practices for the

Management of Hepatitis C: Screening, Linkage to Care, and Treatment -

(CME activity) ~ West Hollywood, California

2011 Medical Grand Rounds ~ Hepatitis C: Diagnosis and Management (CME

activity) ~ Harbor-UCLA, Torrance, California

2011 Post-Conference Update 2010: ACG and AASLD. Association of Black

Women Physicians, Rancho Palos Verdes, California

2011 Hepatitis B: From Diagnosis to Treatment. Kern Medical Center,

Bakersfield, California

2011 Hepatitis C: From Diagnosis to Management (CME activity) ~ Asian

Physician Medical Group ~ Rosemead, California

2011 Hepatocellular Carcinoma: Risk Factors, Screening, Surveillance, and

Staging (CME activity). Improving Medical Practice by Advancing

Clinical Therapeutics, Los Angeles, California

2011 Medical Grand Rounds ~Viral Hepatitis: Epidemiology, Diagnosis,

Treatment (CME activity) ~ West Hills Medical Center, West Hills,

California

2011 Medical Grand Rounds ~ Hepatitis C: Diagnosis and Management.

Tillamook Country General Hospital, Tillamook, Oregon

2011 Medical Grand Rounds ~ Address Hepatitis C Clinical Gaps among

Special Patient Populations. (CME activity) ~ Veteran Affairs Los

Angeles Ambulatory Care Center, Los Angeles, California.

2011lamook National End Stage Liver Disease Training Program and Treatment

Update 2011 (CME activity) ~ Scripps Clinic, Pasadena, California

2011 Hepatitis B Management Considerations for Women of Child-Bearing

Age and Pregnancy (CME activity) ~ Asian Physician Medical Group ~

Rosemead, California

2011 Medical Grand Rounds ~ Impact of Chronic Liver Disease (CME

activity) ~ St. Joseph's Medical Center ~ Modesto, California

2011 Ninth Annual Offsite CME Meeting ~ Hepatitis B Management

Considerations for Women of Childbearing Age and Pregnancy (CME

activity). Armenian American Medical Society of California ~ Las Vegas,

Nevada

2011 Gastroenterology Conference 2011 ~ ABCs of Hepatitis (CME

activity) ~ Antelope Valley Hospital, Lancaster, California.

2011 Infectious Disease Grand Rounds ~ Emerging Therapy for Chronic

Hepatitis C (CME activity) ~ Los Angeles County and the University of

California Medical Center ~ Los Angeles, California

2011 Fifth Annual UCLA Liver Diseases Symposium ~ Current Treatment of

Saab 19

Hepatitis C~ (CME activity) ~ University of California Los Angeles,

Pasadena, California

2011 Plenary Session ~ 9th Annual Hepatitis Summit Viral Hepatitis Overview –

Hepatitis C Task Force for Los Angeles ~ Los Angeles, California

2012 Annual Spring CME Conference ~ Clinical Perspectives in the

Management of Chronic Hepatitis B Infection ~ (CME activity) ~

Armenian American Medical Society Glendale, California

2012 American College of Physicians Annual Meeting ~ Chronic Hepatitis:

The Bs and Cs (CME activity) ~ American College of Physicians ~ New

Orleans, Louisiana

2012 2012 Annual Federal Hemophilia Treatment Centers Conference for

Region IX “Challenges of Living Longer with Hemophilia” ~ Hepatitis C

– Update on the Latest Treatments ~ Santa Monica, California

2012 Hyponatremia – Clinical Implications and Managments. Santa Clara

Valley Medical Center, Santa Clara, California.

2012 Hepatitis C: Understanding and Combating a Hidden Disease(CEU

activity) ~ The California Partnership, Los Angeles, California

2012 National Hepatitis B and C Training Program and Treatment Update 2012

(CME activity) ~ Scripps Clinic, Los Angeles, California

2012 National End Stage Liver Disease Training Program and Treatment

Update 2012 (CME activity) ~ Scripps Clinic, Hollywood, California

2012 Update! Advances in Hepatitis C Current and Future Treatment – The

World is Changing! ~ National AIDS Treatment Advocacy Project, Los

Angeles

2012 Unmet Needs in Hepatitis C (CME activity)~ University of Santo Tomas

Medical Alumni Association in America Convention - Caesars Palace

Convention Center, Las Vegas, Nevada

2012 Hepatitis C. Update on Direct Acting Agent Therapy (CME Activity) ~

National Liver Conference 2012, San Antonio, Texas

2012 Medical Grand Rounds ~ Hepatitis A through C: Diagnosis, Natural

History and Management (CME activity) ~ Torrance Memorial Medical

Center, Torrance, California

2012 Sixth Annual UCLA Liver Diseases Symposium ~ Hepatitis C: Update

on Screening, Epidemiology, and Management~ (CME activity) ~

University of California Los Angeles, Pasadena, California

2012 Medical Grand Rounds ~ Fatty Liver Manifestation of the Metabolic

Syndrome: Diagnosis, Natural History and Treatment (CME activity) ~

West Hills Hospital, West Hills, California

2013 Medical Grand Rounds ~ Fatty Liver Manifestation – A Sleeping

Giant (CME activity) ~ Providence Holy Cross Medical Center, Mission

Hills, California

2013 Infectious Disease Grand Round ~ Management Considerations for

Hepatitis B Co-Infection with Hepatitis C or HIV. University of Southern

California Medical Center, Los Angeles, California

2013 Liver Transplant Grand Round ~ Fatty Liver and Liver Transplantation.

University of California Los Angeles, Los Angeles, California

Saab 20

2013 Medical Grand Rounds ~ Clinical Advances in the Management of

Cirrhosis and its Complications (CME Activity) ~ Eisenhower Medical

Center, Rancho Mirage, California.

2013 Viral Hepatitis Liver Transplantation: Pre and Post-Transplant

Management Clinical Symposium. Hepatitis B: HBIG Out, Antivirals In.

American Association for the Study of Liver Disease. Digestive Disease

Week, Orlando, Florida.

2013 Chronic Hepatitis B: New Trends and Treatment (CME Activity). 21st

USTMAAA Medical Convention. Waikiki, Hawaii.

2013 Chronic Hepatitis C: Diagnosis and Management (CME Activity). 21st

USTMAAA Medical Convention. Waikiki, Hawaii.

2013 National Hepatitis B and C Training Program and Treatment Update

2013 (CME activity) ~ Hepatitis C. Scripps Clinic, Los Angeles,

California

2013 American College Gastroenterology 2013 (CME Activity) ~ The

Incidental Liver Lesion,: How to Follow, When to Refer San Diego,

California

2013 Seventh Annual UCLA Liver Diseases Symposium ~ Hepatitis C: Present

and Future Therapy ~ (CME activity) ~ University of California Los


2013 Chronic Hepatitis C Bridging Diagnosis and Management ~ (CME

activity) American Association of Critical Care Nurses. Costa Mesa,

California.

2013 Chronic Hepatitis C ~ Screening and Diagnosis ~ (CME activity)

Armenian American Nurses Association. Studio City, California

2014 GI Issues for the Primary Care Physician ~ Clinical Advances in the

Management of Cirrhosis and Its Complications ~ (CME activity) ~ Los

Angeles, California

2014 2nd Annual UCLA-Mellinkoff Gastroenterology Symposium

Therapeutics in Gastroenterology ~ Treatment of Hepatitis C (CME

activity) ~ Los Angeles, California

2014 Third Spring Conference Medical Update ~ Clinical Perspectives in the

Management of Chronic Hepatitis C Infection~ (CME activity) ~

Armenian American Medical Association. Glendale, California

2014 Medical – Surgical Grand Rounds ~ Fatty Liver – The Sleeping Giant

(CME Activity) St Vincent’s Medical Center, Los Angeles, California

2014 Medical Grand Rounds ~ Viral Hepatitis (CME Activity) Little

Company of Mary- San Pedro, California

2014 Phillipine Medical Society of Northern California ~ Complications of

Cirrhosis ~ Encephalopathy, Burlingame, California

2014 National Hepatitis B and C Training Program and Treatment Update

2014 (CME activity) ~ Hepatitis C. Scripps Clinic, Hollywood, California

2014 Surgical Grand Rounds ~ Update on Hepatology & Infectious

Diseases of the Liver for Surgeons. University of California Los Angeles

Medical Center.

2014 Annual Emerging Topics in Liver Disease Conference ~ Management

of Hepatitis C in the Era of Direct Acting Antiviral Therapy (CME

activity) ~ Houston, Texas

Saab 21

2014 The Seventeenth Conference on Health Care of the Chinese in North

America "Preventive Care: Opportunities and Challenges" ~

Hepatocellular Carcinoma, Millennium Biltmore Hotel, Los Angeles,

California

2014 Hepatitis C: New Developments in Treatment (CME activity) ~ Infectious

Disease Association of California, Irvine, California

2014 Eighth Annual UCLA Liver Diseases Symposium ~ Hepatitis C:

Current and Future Therapy ~ (CME activity) ~ University of California

Los Angeles, Los Angeles, California

2014 Hepatitis C Panel Discussant ~. Southern California Society of

Gastroenterology ~ Ritz-Carlton, Laguna Beach

2015 Medical Grand Rounds ~ Advances in Hepatitis C Management and

Treatment. Providence Tarzana Medical Center, Tarzana, Georgia

2015 Medical Grand Rounds ~ Fatty Liver. Northridge Medical Center,

Northridge, California

2015 Women's Health Case Conference ~ Fatty Liver Disease (CME activity) ~


2015 Division of Nephrology Grand Rounds ~ New Advances in Hepatitis C ~


2015 Spotlight on Hepatitis C Infection (CME activity) ~ Pri-Med Southwest

Annual Conference ~ Houston, Texas

2015 Third Annual UCLA-Mellinkoff Gastroenterology Symposium

Therapeutics in Gastroenterology ~ Viral Hepatitis. A New Dawn

(CME activity) ~ Los Angeles, California

2015 Pri-Med West Annual Conference ~Advances in Hepatitis C Infection

(CME activity) ~ Anaheim, California

2015 14th Annual GI Pow Wow! Chronic Hepatitis C - Update in Diagnosis and

Management (CME activity). ~ Denver, Colorado

2015 Pri-Med West Annual Conference ~Advances in Chronic Hepatitis C

Infection (CME activity) ~ Long Beach, California

2015 Department of Medicine Grand Rounds ~ New Advances in Hepatitis C

(CME activity) ~ Providence Holy Cross Medical Center, Mission Hills,

California

2015lamook National End Stage Liver Disease Training Program and Treatment

Update 2015 (CME activity) ~ Hepatitis C~ Scripps Clinic, Los Angeles,

California.

2015 Treating Hepatitis C related Cirrhosis. Texas Tech Health Science Center.

El Paso, Texas

2015 Third Annual End Stage Liver Disease Training Program and

Treatment Update 2015 (CME activity) ~ Scripps Clinic, La Jolla,

California

2015 Diablo Society of Health-System Pharmacists ~ Hepatic encephalopathy ~

Walnut Creek, California

2015 Hepatitis C – Cure has Arrive: Care and Treatment Management ~

National AIDS Treatment Advocacy Project ~ St Anne’s Conference, Los

Angeles, California

2015 Chronic Hepatitis C Treatment ~ Tule River Indian Reservation,

Porterville, California

Saab 22

2015 Current and Future Trends in Hepatitis C ~ 38th Annual Recognition

Program, Bakersfield Memorial Hospital, Bakersfield, California

2015 Medical Grand Rounds ~ Therapy in Difficult to Treat Patients with

Hepatitis C (CME activity) City of Hope, Duarte, California.

2015 Treating Patients with Advanced Liver Disease and Liver Transplant

Recipients for Hepatitis B (CME activity). California Northstate

University. Elk Grove, California.

2015 Medical Grand Rounds ~ Fatty Liver (CME activity) West Hills

Hospitals and Medical Center, West Hills, California

2015 Ninth Annual UCLA Liver Diseases Symposium ~ Current and Future

Hepatitis C Therapies (CME activity) ~ University of California Los

Angeles, Pasadena, California Pasadena, California

2015 Pri-Med West Annual Conference ~Advances in the Management of

Chronic Hepatitis C Infection (CME activity) ~ Los Angeles, California

2015 Medial Grand Rounds ~ Fatty Liver (CME Activity) ~ St. Joseph Medical

Center, Burbank, California.

2015 Medical Grand Rounds ~ Current Trends in Fatty Liver (CME activity) ~

Providence Holy Cross Medical Center, Mission Hills, California

2015 American Academy of Addiction Psychiatry ~ Advances in the

Management of Chronic Hepatitis C (CME) ~ Huntington Beach,

California

2015 Liver Summit 2015 ~ A Clinical Update on Primary Biliary Cirrhosis,

Non-alcoholic Fatty Liver Disease, Chronic Hepatitis B and C, Cirrhosis,

and Liver Cancer (CME) ~ Pasadena, California

2016 Advances in Hepatitis C Treatment ~ UCLA Motion Pictures Medical

Group, Woodland Hills, California.

2016 UCLA Clinical and Contemporary IR 2016 ~ New Treatments for

Hepatitis C (CME) ~ Santa Monica, California

2016 Fourth Annual UCLA-Mellinkoff Gastroenterology and Hepatology

Symposium. Current Practice and Future Trends in Gastroenterology ~

Hepatitis C ~ Vanishing Disease (CME activity) ~ Beverly Hills,

California

2016 Division of Infectious Diseases Medical Conference ~ Evolving

Management of Hepatitis C/HIV Coinfection (CME activity) ~ University

of California Irvine Medical Center, Orange, California

2016 Annual Internal Medicine Conference. Chronic Hepatitis C

Treatment Guidelines: Best Practices for Achieving a Cure (CME

activity) ~ Armenian American Medical Society of California.

Glendale, California

2016 Hepatitis C: A Primer for Primary Care (CME activity) ~ UCLA

Primary Care 2016 ~ Las Vegas, Nevada

2016 33rd Annual Spring Update. (CME activity) ~ Advances in Hepatitis C ~

Saint Francis Hospital, Memphis, Tennessee

2016 Clinical Symposium ~ Cost-Effectiveness of HCV Therapy by

Genotype. Maximizing the Value of Care for Patients with Chronic

HCV Infection. Digestive Disease Week. San Diego, California

2016 Medical Grand Rounds ~ Advanced in Liver Transplantation (CME

activity) ~ Northridge Hospital Medical Center, Northridge, California

Saab 23

2016 Nurse Course. Update on Hepatitis C. Laguna Niguel, California

2016 Post-Digestive Disease Week. Hepatitis Hot Topic: Hepatitis C (CME

activity). Southern California Society of Gastroenterology. Laguna

Niguel, California

2016 Rheumatology Grand Rounds ~ Autoimmune hepatitis ~ University of

California Los Angeles, Los Angeles, California

2016 40th American College of Osteopathic Family Physicians Annual

Scientific Medical Seminar. Chronic Hepatitis C ~ Screening, Diagnosing

and Referring. ACPFPCA, Anaheim, California.

2016 Tenth Annual UCLA Liver Diseases Symposium ~ Update on Chronic

Hepatitis C Management and Therapy (CME activity) ~ University of

California Los Angeles, Pasadena, California Pasadena, California

2016 Hepatic Encephalopathy: Economic and Social Burden, Hospital

Readmission and Cognition. Chronic Liver Disease Foundation, Chicago,

Illinois

2016 Medical/Surgical Grand Rounds ~ Liver Cirrhosis (CME/MOC activity) ~

St Vincent Medical Center, Los Angeles, California

2016 Medical Grand Rounds ~ Primary Biliary Cholangitis. Kern Medical

Center, Bakersfield, California

2016 Hepatitis C Case Discussion (CME activity) ~ Southern California

Society of Gastroenterology. Laguna Beach, California.

2017 Department of Medicine Grand Rounds ~ Current Management of

Hepatitis C ~ Working Toward Elimination (CME activity) ~ Harbor-

UCLA Medical Center, Torrance, Los Angeles, California

2017 Department of Medicine Grand Rounds ~ Advances in Chronic Hepatitis

C ~ Olive View - UCLA Medical Center, Sylmar, California

2017 Department of Medicine Grand Rounds ~ Hepatitis C Advances – (CME

activity) ~ Providence Holy Cross Medical Center, Mission Hills,

California

2017 Department of Family Medicine Grand Rounds ~ Current Concepts

in Cirrhosis– (CME activity) ~ UCLA- Santa Monica Medical Center,

Santa Monica, California

2017 Fifth Annual UCLA-Mellinkoff Gastroenterology and Hepatology

Symposium. Current Practice and Future Trends in Gastroenterology ~

Update on Hepatitis C (CME activity) ~ Beverly Hills, California

2017 Rocky Mountain Gastroenterology’s 16th Annual GI Pow-Wow

Conference ~ Diagnosis and Management of Autoimmune Liver Disease

B (CME activity). Denver, Colorado

2017 Hepatitis C: The Changing Climate in Transplant. (CEU activity).

University of California at Los Angeles, Los Angeles, California

2017 Medical Grand Rounds ~ Update on Primary Biliary Cholangitis (CME

activity). West Hills Hospital and Medical Center, West Hills, California

2017 Pri-Med ~Viral Hepatitis Infection Update (CME activity) ~ Irving, Texas

2017 11th Annual UCLA Liver Diseases Symposium ~ Best Options for

Treatment of Hepatitis C ~ (CME activity) ~ University of California Los


2017 Medical Grand Rounds ~ Hepatitis C ~ The Final Countdown (CME

activity). Harbor-UCLA Medical Center, Torrance, California

Saab 24

2017 Annual Public Health Investigation Symposium ~ Hepatitis C: The New

Silent Epidemic. Rio Honda Country Club, Downey, California

2017 Hepatitis C Case Discussion – Management Strategies (CME activity) ~

Southern California Society of Gastroenterology. Laguna Beach,

California.

2017 2nd Annual Southern California Kidney Symposium: The Kidney

Crossroads of Whole Body Health and Disease ~ Management of

Hepatitis C and Kidney Disease (CME activity). University of Southern

California, Los Angeles, California

2018 Medical Grand Rounds ~ Elimination of Hepatitis C (CME activity) ~

University of California Los Angeles, California.

2018 Nephrology Grand Rounds ~ Association of Hepatitis C and Renal

Disease. University of California Los Angeles, California

2018 Sixth Annual UCLA-Mellinkoff Gastroenterology Symposium

Therapeutics in Gastroenterology ~ Hepatitis C: The Final Chapter


2018 Rocky Mountain Gastroenterology’s 17th Annual GI Pow-Wow

Conference ~ Update on Hemochromatosis (CME activity). Denver,

Colorado

2018 15th Annual Hepatitis C Summit. Hepatitis C: The Fight Continues.

California Endowment, Los Angeles, California

2018 Medical Grand Rounds: Fatty Liver ~ Current Management (CME

activity). Orange Coast Medical Center. Fountain Valley, California

2018 Triple E for Hepatitis C. Engagement, Education and Eradication of HCV

among Patients with Substance Use Disorders. 2018 National Conference

on Alcohol & Addiction Disorder (CME activity). Anaheim, California

2018 Department of Surgery Grand Rounds ~ Elimination of Hepatitis C.

University of California, Los Angeles, Los Angeles, California

2018 2018 Scripps Clinic National Hepatitis B&C Training Program and

Treatment Update. San Gabriel, California.

2018 Emerging Topics in Liver Disease Conference ~ State of the Art Lecture.

Nonalcoholic Fatty Liver Disease: Pathogenesis and Implications for

Medical Management (CME activity) ~ Sherrie and Alan Conover Center

for Liver Disease and Transplantation. Houston Methodist Hospital,

Houston, Texas

2018 Medical Grand Rounds. Fatty Liver. Pathogenesis, Diagnosis and

Treatment (CME activity) ~ Providence Holy Cross Medical Center,

Mission Hills, California A

2018 Rheumatology Grand Rounds. Spectrum of Autoimmune Liver Diseases.

Division of Rheumatology, University of California Los Angeles, Los

Angeles, California.

2018 Medical Update for the Psychiatrist. Hepatic Disease (CME activity).

MasterPsych, Santa Barbara, California

2018 Panel Discussion on Cholestatic Liver Diseases (CME activity). Southern

California Society of Gastroenterology. Laguna Beach, California

2019 PrimMed Annual Meeting. Hepatitis C: From Diagnosis to Cure (CME

activity). Fort Lauderdale, Florida.

2019 Seventh Annual UCLA-Melinkoff Gastroenterology Symposium

Saab 25

Therapeutics in Gastroenterology ~ Eliminating Hepatitis C: From

Diagnosis to Cure. (CME activity) ~ Beverly Hills, California

2019 Department of Medicine Grand Rounds ~ Fatty liver. From Diagnosis and

Management (CME activity). Good Samaritan Hospital, Los Angeles,

California

2019 Regional Summit Series on Gastrointestinal Malignancies (non-CME) ~

Hepatocellular Carcinoma. Pasadena California

2019 Department of Medicine Grand Rounds ~ Fatty Liver ~ Emerging Giant in

Healthcare (CME activity). UCSF Fresno Center. Fresno, California

2019 Department of Medicine Noon Lecture ~ Management of Cirrhosis:

Tailored Care (non-CME activity). UCSF Fresno Center. Fresno,

California

2019 Medicine Grand Rounds ~ Non-Alcoholic Fatty Liver Disease (CME

activity). Providence Holy Cross Medical Center. Mission Hills,

California.

2019 16th Annual Hepatitis C Summit. Identifying and Managing Patients with

Hepatitis C (non-CME activity). Los Angeles, California.

2019 National AIDS Treatment Advocacy Project (non-CME activity) ~ New

Approaches in Treating and Curing Hepatitis C. St Anne’s Conference,


2019 Family Medicine Grand Rounds. Evolution in the management of

Hepatitis C - Changing Epidemiology and Treatment Indications (CME

activity). Santa Monica –UCLA Hospital, Santa Monica, California

2019 Review of Viral Hepatitis, Discovery of HCV and Natural History.

Hepatitis C. (CME activity). Scripps National Hepatitis B&C Training

Program and Treatment Update. Marina del Ray, California.

2019 Diagnostic Testing, Screening, Histology, Cirrhosis and Liver Biopsy.

Hepatitis C. (CME activity). Scripps National Hepatitis B&C Training

Program and Treatment Update. Marina del Ray, California.

2019 Antiviral Therapies for Hepatitis C. Hepatitis C. (CME activity). Scripps

National Hepatitis B&C Training Program and Treatment Update. Marina

del Ray, California.

2019 Updated Data from EASL 2019. Hepatitis C. (CME activity). Scripps

National Hepatitis B&C Training Program and Treatment Update. Marina

del Ray, California.

2019 Thirteenth Annual UCLA Liver Diseases Symposium ~ Hepatitis C:

Current Antiviral Treatments, Risk for Hepatocellular Carcinoma? (CME

activity) ~ University of California Los Angeles, Pasadena, California

2019 Medical Grand Rounds. Non-Alcoholic Fatty Liver Disease (CME

activity) ~Northridge Hospital Medical Center, Northridge, California

2019 Liver Symposium Panel Discussant (CME activity). Southern California

Society of Gastroenterology. Laguna Beach, California.

2020 Liver Transplantation for Alcohol Hepatitis (non-CME activity). Orange

County Gastroenterology Society. Santa Ana, California

2020 2020 Emerging Therapies for PBC, NASH, ESLD and HCC Seminar

Series (CME activity). Scripps Liver Research Consortium. Pasadena,

California.

Saab 26

2020 Eighth Annual UCLA-Melinkoff Gastroenterology Symposium

Therapeutics in Gastroenterology ~ Hepatitis C: The Gift That Keeps on

Giving (CME activity) ~ Beverly Hills, California

2020 Covid-19 and the Liver. Hot Topics in Cirrhosis: A Case-Based Approach

to Hepatorenal Syndrome and Acute Kidney Injury in Liver Disease.


2020 First Steps in HCV Elimination: Improved Screening and Linkage-to-Care

Approaches (CME activity). Orange County Gastroenterology Society.


Saab 27

International

2006 Hepatitis C Symposium ~ What about the Relapser/Non-responder? Treat

or Maintain? ~ Sydney, Australia

2006 Hepatitis C Symposium ~ What’s in Store in the Future? ~ Sydney,

Australia

2007 Current Practices and Challenges of Hepatitis C Treatment for Special

Groups in the USA: Hepatitis C Disease Progression, Liver Transplant,

and End-Stage Renal Disease ~Bhusan, Korea

2008 International Hepatology – 2007 AASLD Highlight ~ Congress Chinese

Medical Association ~ Shanghai, China

2008 Extended Donors in Liver Transplantation ~ American Transplant

Congress ~ Toronto, Canada

2008 Managing Complications of Anti-Hepatitis C Therapy ~ American

Transplant Congress ~ Toronto, Canada

2008 Pregnancy and Liver Transplantation ~Joint International Congress of

ILTS, ELITA, and LICAGE ~ Paris, France

2009 State of Liver Transplantation: Current Problems, Future Solutions ~

Hepatitis C Treatments: On the Horizon ~ International Liver

Transplantation Society New York, New York

2009 ILTS Postgraduate Course: Quality of Life for Adult Recipients ~

International Liver Transplantation Society, Boston, Massachusetts

2011 Curbside Consultation and Case Discussion: Complications of Cirrhosis

(Meet the Professor Luncheon). Digestive Disease Week. Chicago,

Illinois

2011 2011 EASL Special Conference on Liver Transplantation. Cardiovascular

Complications: Minimizing Risks. ~ Lisbon, Portugal

2012 Scientific Committee of the Saudi Association of Liver Diseases and

Transplantation. Hepatitis C Treatment in the Transplant Setting.

Dammam, Saudi Arabia

2013 Saudi International Congress on New Frontiers in Organ Transplantation

2013. Advances in Hepatitis C Management Post Liver Transplantation.

Riyadh, Saudi Arabia

2013 Hepatitis B Screening (CME Activity). Internal Medicine

Multidisciplinary Session. 11th Armenian Medical World Congress. Los

Angeles, California

2014 Congreso de Medicina y Especialidades Kennedy Simposi de Hepatologia.

Update on Chronic Hepatitis B and C Treatment; Treatment of NASH;

Treatment of Hepatocellular Carcinoma; Indications and Contraindications

for Liver Transplantation. Guayaquil, Ecuador.

2015 New Direct Acting Agents: Can we Afford Them and How Should we use

them Before and After Liver Transplantation. Alberta Society of

Gastroenterology, Lake Louise, Alberta.

2015 Vanguard Grand Round Case Presentation. International Liver Transplant

Society, Chicago, Illinois

2018 Hepatitis C Elimination. The 15th National Congress of Chinese Society of

Infectious Disease. Beijing, China

Saab 28

2019 New Insights into the Viral Hepatitis Managements. Goals Beyond

Achieving the Goals of Chronic Hepatitis B Therapy. Hong Kong

Association for the Study of Liver Diseases, Hong Kong, China.

2019 Middle East Liver Forum. Managing At-Risk Populations with Hepatitis

C: Drug Users and Prisoners (Royal College of Physicians activity).

Dubai, United Arab Emirates.

2019 Middle East Liver Forum. Screening and Linkage to Care: PWIDs and

Others (Royal College of Physicians activity). Dubai, United Arab

Emirates.

Saab 29

PATIENT EDUCATION/MULTIMEDIA

2000 Organs for Life, Live Broadcast, Host, Jerry Reilly

2001 Enfermedades Del Hígado: Los Especialistas Responden (in Spanish)

Symposium Co-director, American Liver Foundation, Los Angeles

Chapter

2002 Enfermedades Del Hígado: Los Especialistas Responden (in Spanish)

American Liver Foundation, Los Angeles Chapter

2002 Viral hepatitis, Latino Issues Forum, Los Angeles

2003 Enfermedades Del Hígado (in Spanish) Symposium Co-director,

University of California Los Angeles

2003 La Hepatitis C, Public Service Announcement, Radio Super Estrella 107.1

FM

2003 Doctors: Diet Supplement May Harm Liver, NBC Nightly Television

News

2003 Un padecimiento que no se siente, La Opinion (in Spanish)

2003 Liver damage and cirrhosis, NBC Nightly Television News

2004 Liver Diseases, Symposium Director, University of California Los

Angeles Medical Center and the American Liver Foundation, Los Angeles

Chapter

2004 Breaking Point: Danger and Diet, Fox News

2004 La Hepatitis C, Public Service Announcement, Radio Super Estrella 107.1

FM

2004 Hepatitis C Overview, Hepatitis C Summit, Hepatitis C Task Force for

Los Angeles County

2004 Protect your Liver and Pancreas (in English and Spanish), Community

Seminar, Research Center for Alcohol Liver and Pancreatic Diseases, Los

Angeles

2004 Acetaminophen toxicity, Live Interview , Max Aub,

“Hoy por Hoy” for W Radio XETRA 690AM (in Spanish)

2005 Liver Disease Update, Symposium Director, University of California Los

Angeles Medical Center and the American Liver Foundation, Los Angeles

Chapter

2005 Knowing your Liver, Kiwanis Organization, Downey, California

2005 Enfermedades Del Hígado (in Spanish), Symposium Co-director,

University of California Los Angeles

2006 Liver Diseases Update, Symposium Director and Speaker, University of

California Los Angeles Medical Center and the American Liver

Foundation, Los Angeles Chapter

2006 Liver Diseases among Latinos, Live Interview, Juan Carlos Show, Radio

Super 830 AM (in Spanish)

2007 Liver Diseases Update. Symposium Director and Speaker, University of


Foundation

2007 Hepatitis C. Live Panel, Seventh Annual KLJH Women’s Health Forum,

KLJH 102.3FM

2007 Hepatitis C and Alcohol. Alcohol and Your Health - 4th Annual

Community Seminar, Los Angeles, University of Southern California

Saab 30

2007 “A Silent Disease that Speaks Volumes”. Article in Westlake Magazine

October/November 2007; page 80.

2008 “Palisades Expert Warns about Liver Disease”. Article in Palisadian-Post

January 2008.

2008 La Hepatitis C. Aquí y Ahora for Univision Television Station (in

Spanish)



Foundation

2008 Hepatitis C: Diagnosis and Management. Liver Wellness. Liver Health

and Disease Prevention. Los Angeles, California

2008 What the Liver Does. Moving Mountains. Sacramento, California

2009 Want to be a Doctor? Korean PBS, Airs in South Korea

2009 Liver Diseases – Update on Diagnosis, Complications, and

Management. Symposium Director, University of California Los Angeles

Medical Center

2010 What your liver can do for you! Corpus Christi School, Pacific Palisades,

California



Medical Center

2010 Viral hepatitis, alcohol, and liver transplantation. USC Institute for

Health Promotion and Disease Prevention Research. Alhambra, California

2011 Department of Medicine Grand Rounds ~ Management of Cirrhosis, and

its Complications (CME activity) ~ Providence Holy Cross Medical

Center, California

2011 Best Practices for the Management of Hepatitis C: Screening,

Linkage to Care, and Treatment (CME activity). Association of Black

Woman Physicians, West Hollywood, California

2011 Hepatitis B: From Diagnosis to Treatment (CME activity) ~ Moving

Mountains Redding, California

2011 A Future in Health Care ~ UCLA American Medical Women’s

Association ~Los Angeles, CA

2011 Hepatitis C. Knowledge is Power. K-Power 105.9 ~ Los Angeles, CA

2012 Liver Diseases – What the Liver Can do for You! Speaker and

Symposium Director, University of California Los Angeles Medical

Center

2013 Liver and Hepatitis: Advances in Hepatitis C Treatment Strategies:

Understanding Patient Care and New Drugs. Los Angeles, California.

2014 Hepatitis C drug worth the price: Opposing View. July 16, 2014

USA Today (op-ed)



Foundation

2014 Hepatitis C: Management, Treatment Strategies and New Drugs for

Cure. St Anne’s. Los Angeles, California.

2014 Advances in Hepatitis C Management and Treatment. Loudermilk

Center, Atlanta, Georgia

Saab 31

2014 Strategies in Hepatitis C. https://smp.newshq.businesswire.com/node/1065

2014 Liver Interview on Hepatitis C , Doctor Radio, Sirius XM 81.

2015 Hepatitis C: Are you at Risk. Healthafter50. Health Advice from

America’s Leading Doctors ~ Scientific American Consumer Health.

Issue September 2015. Page 6.

2015 HCV at a Crossroad: The Pre- or Post-Transplant Treatment Debate.

HCVnext. 2015:9-15

2015 Liver Diseases Update 2015. Symposium Director and Speaker,

University of California Los Angeles Medical Center, Los Angeles,

California

2016 New Hepatitis C Drug is a Game Changer. Bottom Line. On the news.

Bottom Line Personal publication.

2016 Hepatitis Awareness. Hepatitis C Screening. St John Coptic

Orthodox Church. Covina, California.

2016 Hepatitis Awareness Month. Hepatitis C Screening. St Peter and Paul

Coptic Orthodox Church. Santa Monica, California

2016 World Hepatitis Day Press Conference, Emcee, St Vincent Medical

Center, Los Angeles, California

2016 Hepatitis Awareness. Hepatitis C Screening. Archangel Michael

Coptic Orthodox Church. Santa Ana, California

2016 14th Annual Hepatitis C Summit. Understanding New HCV

Treatment Options. Los Angeles, California

2017 American Liver Foundation Ask the Experts Seminar: Update on Viral

Hepatitis B and C. Culver City, California



Medical Center, Los Angeles, California

2017 Hepatitis C: Final Countdown, St Anne’s Conference Center. Los Angeles,

California.

2018 Current Trends in Liver Cancer. KNX1070 News. Los Angeles, California

2018 Liver Diseases – Alcohol Liver Disease. Patient Symposium Director,

University of California Los Angeles Medical Center, Los Angeles,

California

2018 Hepatitis C: Working Toward Elimination. St Anne’s Conference Center.


2018 12th Annual UCLA Liver Diseases Symposium ~ Treatment and

Epidemiology of Hepatitis C Infection, Present, and Future (CME activity)

~ University of California Los Angeles, Pasadena, California

2018 Chairperson, American Liver Foundation. 11th Annual Liver Life Walk

Los Angeles. Santa Monica, California

2018 Hepatitis B Reactivation in Patients Treated for Hepatitis C.

Consultant360 Podcast

2019 Hepatocellular Carcinoma. Patient Symposium Director, Ronald Reagan

Medical Center, University of California Los Angeles, Los Angeles,

California

2019 Obesity and Fatty Liver Disease: The Link Between Metabolic Disorders

and NASH. HealthWell Foundation.

https://smp.newshq.businesswire.com/node/1065

Saab 32

http://www.realworldhealthcare.org/2019/09/obesity-and-fatty-liver-

disease-the-link-between-metabolic-disorders-and-nash/

2019 Coronavirus Overview for Liver Disease Patients & Caregivers. American

Liver Foundation.

2020 Covid-19 and the Liver. American Liver Foundation Live Webcast.

https://urldefense.proofpoint.com/v2/url?u=http-3A__www.realworldhealthcare.org_2019_09_obesity-2Dand-2Dfatty-2Dliver-2Ddisease-2Dthe-2Dlink-2Dbetween-2Dmetabolic-2Ddisorders-2Dand-2Dnash_&d=DwMFAg&c=UXmaowRpu5bLSLEQRunJ2z-YIUZuUoa9Rw_x449Hd_Y&r=UjtOPL-qhyQ1iEqXSI8cP3Pvs4Mk27vE_vInSzVQmfc&m=7Fc3VRnC2hgwSjIOZeKjqiaLEog1blGVo8RdJjnvWuo&s=KsG0KGkX1ZbfGw2iGAz-bfeu3BLJtxN1G8IvXhUezQY&e=

https://urldefense.proofpoint.com/v2/url?u=http-3A__www.realworldhealthcare.org_2019_09_obesity-2Dand-2Dfatty-2Dliver-2Ddisease-2Dthe-2Dlink-2Dbetween-2Dmetabolic-2Ddisorders-2Dand-2Dnash_&d=DwMFAg&c=UXmaowRpu5bLSLEQRunJ2z-YIUZuUoa9Rw_x449Hd_Y&r=UjtOPL-qhyQ1iEqXSI8cP3Pvs4Mk27vE_vInSzVQmfc&m=7Fc3VRnC2hgwSjIOZeKjqiaLEog1blGVo8RdJjnvWuo&s=KsG0KGkX1ZbfGw2iGAz-bfeu3BLJtxN1G8IvXhUezQY&e=

Saab 33

PUBLICATIONS

A. RESEARCH PAPERS - PEER REVIEWED

1. Silva JA, Leong GB, Saab S, Wine DB. Misidentification syndromes; facial

misrecognition and dysmorphic symptoms. Psychosomatics 1992; 33:471-472.

2. Silva JA, Leong GB, Wine DB, Saab S. Evolving misidentification syndromes and

facial misrecognition deficits. Can J Psychiatry 1992; 37:574-576.

3. Saab S, Rickman LS, Lyche KD. Ascites and the acquired immunodeficiency syndrome:

report of fifty-four cases. Medicine 1996; 75:131-141.

4. Saab S, Venkataramani A, Behling CA, Savides TJ. Gastric mucosal calcinosis in a

patient with dyspepsia. J Clin Gastroenterol 1996;22:156-157.

5. Saab S, Venkataramani A, Yao F. Possible granulomatous hepatitis following

dicloxacillin therapy. J Clin Gastroenterol 1996;22:163-164.

6. Saab S, Rickman LS. Diagnostic features of tuberculous peritonitis. Am J Med

1996;101:568-569.

7. Saab S, Yao F. Fibrolamellar hepatocellular carcinoma: case reports and a review of the

literature. Dig Dis Sci 1996;41:1981-1988.

8. Ruiz MA, Saab S, Rickman LS. The clinical detection of scleral icterus: observations of

multiple examiners. Military Medicine 1997;162:560-563.

9. Yao F, Behling CA, Saab S, Li S, Hart M, Lyche KD. Trimethoprim-

Sulfamethoxazole induced vanishing bile duct syndrome. Am J Gastroenterol

1997;92:167-9

10. Tucker WN, Saab S, Rickman LS, Mathews WC. The scratch test is unreliable for

detecting the liver edge. J Clin Gastroenterol 1997;25:410-414.

11. Saab S, Corr MP, Weisman MH. Corticosteroids and systemic lupus erythematosus

pancreatitis? Case series and review of the literature. J Rheumatol 1998;25:801-806.

12. Saab S, Martin P. Tests for acute and chronic viral hepatitis. Postgrad Med

2000;107:123-34.

13. Leopoldt D, Yee HF Jr, Saab S, Rozengurt E. Dissociation of tyrosine phosphorylation

of p125Fak, p130Cas and paxillin from ERK activation in Swiss 3T3 cells stimulated by

bombesin or platelet-derived growth factor. J Cell Physiol 2000;183:208-220.

14. Saab S, Soliman GY, Han SH, Machicado GA, Roth BE, Kunder G, Farmer DG,

Ghobrial RM, Martin P, Busuttil RW, Bedford RA. Endoscopic management of biliary

leaks following t-tube removal in liver transplant recipients: nasobiliary drainage vs

biliary stenting. Liv Transpl 2000;6:627-632.

15. Saab S, Martin P, Yee HF Jr. A simple cost-decision analysis model for comparing two

strategies for hepatitis A vaccination. Am J Med 2000;109:241-244.

16. Saab S, Martin P, Han SHB, Kim M, Wright TL, Busuttil RW. Successful orthotopic

liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus.

Gastroenterol 2000;119:1382-1384.

17. Saab S, Martin P, Brezina M, Gitnick G, Yee HF Jr. Serum alanine aminotransferase in

hepatitis C screening of patients on hemodialysis. Am J Kid Dis 2001;37:308-315.

18. Saab S, Brezina M, Gitnick G, Martin P, Yee HF Jr. Hepatitis C antibody based testing is

the preferred strategy for hepatitis C screening in hemodialysis patients. Am J Kid Dis

2001;38:91-97.

19. Shimoda M, Saab S, Ghobrial RM, Farmer DG, Han SHB, Bedford RA, Goldstein LI,

Martin P, Busuttil RW. A cost-effective analysis of biliary anastomosis with or without

T-tube after orthotopic liver transplantation. Am J Transpl 2001;1:157-161.

Saab 34

20. Ghobrial RM, Steadman R, Gornbein J, Lassman C, Holt CD, Chen P, Farmer DG,

Yersiz H, Danino N, Collisson E, Baquarizo A, Han S, Saab S, Goldstein LI, Donovan

JA, Esrason K, Busuttil RW. A 10-year experience of liver transplantation for hepatitis c:

analysis of factors determining outcome in over 500 patients. Ann Surg 2001;234:384-

394.

21. Ly D, Yee HF Jr, Martin P, Brezina M, Gitnick G, Saab S. Hepatitis B immunization

causes detectable hepatitis B surface antigen in hemodialysis patients. Am J

Gastroenterol 2002;97:138-141.

22. Anselmo DM, Ghobrial RM, Jung LC, Weaver M, Cao C, Saab S, Kunder G, Chen PW,

Farmer DG, Yersiz H, Baquerizo A, Geevarghese S, Han SH, Goldstein L, Holt CD,

Gornbein JA, Busuttil RW. New era of liver transplantation for hepatitis B: a 17-year

single-center experience. Ann Surg 2002;235:611-20.

23. Saab S, Ly D, Lin R, Rojter SE, Han S, Ghobrial RM, Busuttil RW. Cost-effectiveness

of treating hepatitis C after liver transplantation. Liv Transpl 2002;8:449-57.

24. Saab S, Weston S, Ly D, Brezina M, Yee HF Jr, Han S, Gitnick G. A cost-effective

decision analysis model comparing two strategies for hepatitis B immunity in the

hemodialysis community. Vaccine 2002;20:3230-3235.

25. Ghobrial RM, Gornbein J, Steadman R, Danino N, Markmann JF, Holt C, Anselmo D,

Amersi F, Chen P, Farmer DG, Han S, Derazo F, Saab S, Goldstein LI, McDiarmid SV,

Busuttil RW. Pretransplant Model to Predict Posttransplant Survival in Liver Transplant

Patients. Ann Surg 2002;236:315-323.

26. Ghobrial RM, Saab S, Lassman C, Lu DS, Raman S, Limanond P, Kunder G, Marks K,

Amersi F, Anselmo D, Chen P, Farmer D, Han S, Durazo F, Goldstein LI, Busuttil RW.

Donor and recipient outcomes in right lobe adult living donor liver transplantation. Liver

Transpl 2002;8:901-9.

27. Nyamathi A, Robbins WA, Fahey JL, Wiley D, Pekler VA, Longshore D, Robins TA,

Singh J, Saab S. Presence and predictors of hepatitis C virus RNA in the semen of

homeless men. Biol Res Nurs 2002;4:22-30.

28. Saab, S, Tam SP, Tran BN, Melton AC, Tangkijvanich, P, Wong HC, Yee, Jr HF.

Myosin mediates contractile force generation by hepatic stellate cells in response to

endothelin-1. J Biomed Sci, 2002;9:607-12.

29. Han SH, Martin P, Edelstein M, Hu R, Kunder G, Holt C, Saab S, Durazo F, Goldstein

L, Farmer D, Ghobrial RM, Busuttil RW. Conversion from intravenous to intramuscular

hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in

patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver

transplantation. Liver Transpl 2003;9:182-7.

30. Saab S, Hu R, Ibrahim AB, Goldstein LI, Kunder G, Durazo F, Han S, Yersiz H,

Ghobrial RM, Farmer DG, Busuttil RW, Lassman C. Discordance between alanine

aminotransferase and liver histology in liver transplant recipients treated with ribavirin

for recurrent hepatitis C infection. Am J Transpl 2003;3:328-33.

31. Tang SJ, Geevarghese S, Saab S, Martinez D, Van Herle A, Wallace WD, Cortina GR,

Dry S, Busuttil RW. A parathyroid hormone-related protein-secreting metastatic

epithelioid leiomyosarcoma. A case report and review of the literature. Arch Pathol Lab

Med 2003;127:181-5.

32. Farmer DG, Anselmo DM, Ghobrial RM, Yersiz H, McDiarmid SV, Cao C, Weaver M,

Figueroa J, Khan K, Vargas J, Saab S, Han S, Durazo F, Goldstein L, Holt C, Busuttil

RW. Liver transplantation for fulminant hepatic failure: experience with more than 200

patients over a 17-year period. Ann Surg 2003;237:666-76.

Saab 35

33. Saab S, DeRosa V, Nieto J, Durazo F, Han S, Roth B. Cost and clinical outcomes of

primary prophylaxis of variceal bleeding in patients with hepatic cirrhosis: a decision

analytic model. Am J Gastroenterol 2003;98:763-70.

34. Saab S, Wang V, Ibrahim AB, Morrisey M, Durazo F, Han, S, Kunder G, Durazo F,

Yersiz H, Ghobrial RM, Farmer DG, Goldstein LI, Busuttil RW. MELD score as a

predictor of post-orthotopic liver transplantation one-year patient and graft survival. Liver

Transpl 2003;9:473-6.

35. Saab S, Ly D, Nieto J, Kanwal F, Lu D, Durazo F, Han, S, Kunder G, Durazo F, Yersiz

H, Ghobrial RM, Farmer DG, Amado R, Goldstein LI, Tong M, Busuttil RW.

Hepatocellular carcinoma screening in patients waiting for liver transplantation: A

decision analytic model. Liver Transpl 2003;9:672-81. With accompanying editorial.

36. Saab S, Ghobrial RM, Ibrahim AB, Kunder G, Durazo F, Han S, Farmer DG, Yersiz H,

Goldstein LI, Busuttil RW.. Hepatitis C positive grafts may be used in orthotopic liver

transplantation: a matched analysis Am J Transpl 2003;3: 1167-72. With accompanying

editorial.

37. Jacobs RJ, Saab S, Meyerhoff AS. The cost effectiveness of hepatitis immunization for

US college students. J Am Col Health 2003;51:227-236.

38. Saab S, Chang A, Comulada S, Geeverghese SK, Anselmo DM, Kunder G, Durazo F,

Han, S, Kunder G, Durazo F, Yersiz H, Ghobrial RM, Farmer DG, Goldstein LI, Busuttil

RW. Outcomes of hepatitis C and hepatitis B core antibody positive grafts in orthotopic

liver transplantation. Liver Transpl 2003;9:1053-1061.

39. Jacobs RJ, Greenberg DP, Koff R, Saab S, Meyerhoff AS. Regional variation in the

cost-effectiveness of childhood hepatitis A immunization. Ped Infect Dis J 2003;22:904-

914.

40. Jacobs RJ, Saab S, Meyerhoff AS, Koff R. An economic assessment of pre-

immunization screening for hepatitis A and B. Public Health Reports 2003;118:550-8.

41. Ghobrial RM, Saab S, Lassman C, Lu DSK, Raman S, Limanond P, Kunder G, Marks K,

Amersi F, Anselmo D, Chen P, Farmer d, Han S, Durazo F, Goldstein LI, Busuttil RW.

Donor and recipient outcomes in right lobe adult living donor liver transplantation. Liver

Transpl 2003;8:901-909.

42. Kanwal F, Chen D, Ting L, Gornbein J, Saab S, Durazo F, Yersiz H, Farmer D, Ghobrial

RM, Busuttil RW, Han SH. A model to predict the development of mental status changes

of unclear cause after liver transplantation. Liver Transpl 2003;9:1312-9.

43. Limanond P, Raman SS, Lassman C, Sayre J, Ghobrial RM, Busuttil RW, Saab S, Lu

DS. Macrovesicular hepatic steatosis in living related liver donors: Correlation between

CT and histologic findings. Radiology. 2004;230:276-280.

44. Yao FY, Saab S, Bass NB, Hirose r, David Ly, Terrault N, Lazar AA, Bacchetti P,

Ascher NL, Roberts JP. Prediction of survival after liver retransplantation for late graft

failure based on preoperative prognostic scores. Hepatology 2004;39:230-8.

45. Limanond P, Raman SS, Ghobrial RM, Busuttil RW, Saab S, Lu DS. Preoperative

imaging in adult-to-adult living related liver transplant donors: what surgeons want to

know. J Comput Assist Tomogr. 2004;28:149-157.

46. Durazo FA, Lassman C, Han SH, Saab S, Lee NP, Kawano M, Saggi B, Gordon S,

Farmer DG, Yersiz H, Goldstein RL, Ghobrial M, Busuttil RW. Fulminant liver failure

due to usnic Acid for weight loss. Am J Gastroenterol. 2004;99:950-2.

47. Saab S, Nieto J, Ly D, Runyon B. TIPS versus paracentesis for cirrhotic patients with

refractory ascites. The CLib Issue 3, 2004.

Saab 36

48. Saab S, Kalmaz D, Gajjar NA, Hiatt J, Durazo F, Han S, Farmer DG, Ghobrial RM, Yersi

H, Goldstein LI, Lassman CL, Busuttil RW. Outcomes of acute rejection after interferon

therapy in liver transplant recipients. Liver Transpl 2004;10:859-67. With

accompanying editorial.

49. Saab S, Ibrahim AB, Lee C, Shpaner A. Seroepidemiology of hepatitis A in patients

with chronic liver disease. J Viral Hepatitis 2004;11:101-5.

50. Shimoda M, Ghobrial RM, Carmody IC, Anselmo DM, Farmer DG, Yersiz H, Chen P,

Dawson S, Durazo F, Han S, Goldstein LI, Saab S, Hiatt J, Busuttil RW. Predictors of

survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis

C. Liver Transpl. 2004;10:1478-1486.

51. Saab S, Cho D, Quon D, Ibrahim AI, Dong P, Marder V, Logan L. Same day outpatient

transjugular liver biopsies in hemophilia. Haemophilia 2004;10:727-737.

52. Ibrahim AB, Shpaner A, Nieto J, Saab S. Liver fibrosis is accelerated in HIV/HCV

coinfection: a matched analysis. SA Gastroenterol Rev 2004;2:14-17.

53. Saab S, Cho D, Gajjar NA, Ghobrial RM, Lassman CL, Busuttil RW. Recurrent NASH

in a living related liver transplant recipient. J Hepatol 2005;42:148-9.

54. Saab S, Ibrahim AB, Shpaner A, Lee C, Durazo F, Han S, Esrason K, Wu V, Hiatt J,

Farmer DG, Ghobrial RM, Holt C, Yersiz H, Goldstein LI, Tong M, Busuttil RW.

Association between liver disease severity and quality of life in liver transplant

candidates. Liver Transpl 2005;11:218-223. With accompanying editorial.

55. Lu DS, Yu NC, Raman SS, Lassman C, Tong MJ, Britten C, Durazo F, Saab S, Han S,

Finn R, Hiatt JR, Busuttil RW. Percutaneous radiofrequency ablation of hepatocellular

carcinoma as a bridge to liver transplantation. Hepatology. 2005;41:1130-1137.

56. Busuttil RW, Farmer DG, Yersiz H, Hiatt JR, McDiarmid SV, Goldstein LI, Saab S, Han

S, Durazo F, Weaver M, Cao C, Chen T, Lipshutz GS, Holt C, Gordon S, Gornbein J,

Amersi F, Ghobrial RM. Analysis of Long-term Outcomes of 3200 Liver

Transplantations Over Two Decades: A Single-Center Experience. Ann Surg.

2005;241:905-918.

57. Jacobs RJ, Meyerhoff AS, Saab S. Immunization needs of chronic liver disease patients

seen in primary care versus specialist settings. Dig Dis Sci 2005;50:1525-31.

58. Saab S, Niho H, Comulada S, Hiatt J, Durazo F, Han S, Kunder G, Yersiz H, Farmer

DG, Goldstein LI, Ghobrial RM, Busuttil RW. Mortality predictors in liver transplant

recipients with recurrent hepatitis C cirrhosis. Liver Int. 2005;25:940-5.

59. Saab S, Nguyen S, Ibrahim A, Vierling JM, Tong MJ. Management of patients with

cirrhosis in Southern California: results of a practitioner survey. J Clin Gastroenterol

2006;40:156-61.

60. Shiffman ML, S Saab, Feng S, Abecassis MI, Tzakis AG, Goodrich NP, Schaubel DE.

The 2005 SRTR Report on the State of Transplantation: Liver and Intestine

Transplantation in the United States, 1995-2004. Am J Transplant 2006;6:1170-87.

61. Biggins S, Kim WR, Saab S, Balan V, Schiano T, Benson J, Therneau T, Kremers W,

Wiesner R, Kamath P, Terrault N. MELDS: Incorporation of the serum sodium

concentration into MELD: An evidence-based proposal. Gastroenterology

2006;130:1652-60.

62. Saab S, Landaverde C, Ibrahim A, Durazo F, Han S, Farmer DG, Ghobrial M, Holt C,

Yersiz H, Goldstein L, Lipshutz G, Tong MJ, Busuttil RW. Predictors of mortality and

MELD scores changes while waiting for liver transplantation. Experimental and Clinical

Transpl 2006;1:395-9.

Saab 37

63. Saab S, Shpaner A, Zhao Y, Brito I, Durazo F, Han S, Esrason K, Wu V, Hiatt J, Farmer

DG, Ghobrial RM, Holt C, Yersiz H, Goldstein LI, Tong M, Busuttil RW. Prevalence

and risk factors for diabetes mellitus in liver transplant recipients. Am J Transpl

2006;6:1890-5.

64. Cameron AM, Ghobrial RM, Hiatt JR, Carmody IC, Gordon SA, Farmer DG, Yersiz H,

Zimmerman MA, Durazo F, Han SH, Saab S, Gornbein J, Busuttil RW. Effect of

Nonviral Factors on Hepatitis C Recurrence After Liver Transplantation. Ann Surg.

2006;244:563-571.

65. Saab S, Nieto J, Lewis S, Runyon B. TIPS versus paracentesis for cirrhotic patients with

refractory ascites. The CLib Issue 3, 2006.

66. Terrault NA, Shiffman ML, Lok ASF, Saab S, Gillespie BW, Brown RS, Everson GT,

Reddy KR, Farr JH,Kulik LM, Pruett TL, Seeff LB and the A2ALL Study Group. Graft

Survival in Hepatitis C Virus Infected Recipients of Living Donor Liver Transplantation

Versus Deceased-Donor Liver Transplantation. Liver Transpl 2006;13:122-129

67. Saab S, Nguyen S, Collins J, Kunder G, Busuttil RW. Contribution of lymphedema tarda

to chylous ascites after liver transplantation: Case report and review of the literature.

Experimental and Clinical Transpl Exp Clin Transplant. 2006;4:567-70.

68. Otsuka Y, Duffy JP, Saab S, MD, Farmer DG, Ghobrial RM, Hiatt JR, Busuttil RW.

Post-Resection hepatic failure: successful treatment with liver transplantation. Liver

Transpl 2007;13:672-9.

69. Trotter JF, Hill-Callahan MM, Gillespie BW, Nielsen C, Saab S, Shrestha R, Talamantes

MM, Weinrieb RM, and the A2ALL Study Group. Severe psychiatric problems in right

hepatic lobe donors for living donor liver transplantation. Transpl 2007 83:1506-1508.

70. Kim A, Dorn A, Bouajram R, Saab S. The treatment of chronic hepatitis C in HIV-

infected patients: a meta-analysis. HIV Med 2007;8:312-21.

71. Saab S, Mina Oh, Ibrahim AB, Durazo F, Han S, Yersiz H, Farmer DG, Ghobrial RM,

Goldstein LI, Tong MJ, Busuttil RW Risk factors for anemia in live transplant recipients

being treated for recurrent hepatitis C. Liver Transpl 2007;13:1032-8.

72. Saab S, Wiese C, Ibrahim AB, Durazo F, Han S, Yersiz H, Farmer DG, Ghobrial RM,

Goldstein LI, Tong MJ, Busuttil RW. Employment and quality of life in liver transplant

recipients. Liver Transpl 2007; 13: 1330-8.

73. Saab S, Dong M, Joseph T, Tong M. Hepatitis B prophylaxis in patients undergoing

chemotherapy for lymphoma: A decision analysis model. Hepatology. 2007;46:1049-56.

74. Trotter JF, Wisniewski KA, Terrault NA, Kinkhabwala M, Weinrieb RM, Fair JH, Fisher

RA, Koffron AJ, Saab S, Merion RM, and the A2ALL Study Group. Outcomes of donor

evaluation in adult-to-adult living donor liver transplantation. Hepatology 2007;46:1476-

84.

75. Martyak LA, Taqavi E, Saab S. Lamivudine Prophylaxis for Hepatitis B Reactivation in

Patients Undergoing Cytotoxic Chemotherapy: A Systematic Review. Liver International

2008;28:28-38.

76. Yuan Y, Iloeje UH, Hay J, Saab S. An Evaluation of the Cost Effectiveness of Entecavir

versus Lamivudine in suppressing viral replication in Hepatitis BeAg-positive Chronic

Hepatitis B (CHB) Patients. J Managed Care Pharmacy. 2008;14:21-33.

77. Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, Busuttil RW, Tong MJ. Des-

gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic

hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol.

2008;23:1541-8.

Saab 38

78. Saab S, Ibrahim AB, Surit B, Durazo F, Han S, Yersiz H, Farmer DG, Ghobrial RM,

Goldstein LI, Tong MJ, Busuttil RW Pre-transplant variables associated with qualify of

life in liver transplant recipients. Liver International 2008;28:1087-94.

79. Tan J, Joseph T, Saab S. Treating Hepatitis C in the Prison Population is Cost-Saving.

Hepatology 2008;48:1387-95.

80. Shim M, Saab S. Severe hepatotoxicity due to hydroxycut: A case report. Dig Dis Sci.

2009;54:406-8.

81. Nyamathi AM, Liu Y, Marfisee M, Shoptaw S, Gregerson P, Saab S, Leake B, Tyler D,

Gelberg L. Effects of a Nurse Managed Program on Hepatitis Vaccine Completion

among Homeless Adults. Nursing Research 2008 2009;58:13-22.

82. Kanwal F, Spiegel BMR, Hays RD, Durazo F, Han, SB, Saab S, Bolus R, Kim SJ,

Gralnek IM. Prospective Validation of the Short Form Liver Disease Quality of Life

Instrument (The SF-LDQOL). Aliment Pharmacol Ther. 2008;28:1088-101.

83. Campsen J, Blei AT, Emond JC, Everhat JE, Freise CE, Lok AS, Saab S, Wisniewski

KA, Trotter JD, Adult to Adult Living Donor Liver Transplantation Cohort Study Group.

Outcomes of living donor liver transplantation for acute liver failure: The adult-to-adult

living donor liver transplantation cohort study. Liver Transpl. 2008;14:1273-1280.

84. Nyamathi A, Liu Y, Marfisee M, Shoptaw S, Gregerson P, Saab S, Leake B, Tyler D,

Gelberg L. Effects of a Nurse-Managed Program on Hepatitis A and B Vaccine

Completion Among Homeless Adults. Nurs Res. 2009;58:13-22.

85. Tong MJ, Hsien C, Song JJ, Kao JH, Sun HE, Hsu L, Han SH, Durazo FD, Saab S, Blatt

LM. Factors Associated with Progression to Hepatocellular Carcinoma and to Death

from Liver Complications in Patients with HBsAg-Positive Cirrhosis. Dig Dis Sci

2009;54:1337-46.

86. Feasibility of Completing an Accelerated Vaccine Series for Homeless Adults. Nyamathi

AM, Sinha K, Saab S, Marfisee M, Greengold B, Leake B, Tyler D. J Viral Hepat.

2009;16:666-73.

87. Tabibian JH, Asham EH, Goldstein L, Han SH, Saab S, Tong MJ, Busuttil RW, Durazo

FA. Endoscopic treatment with multiple stents for post-liver-transplantation

nonanastomotic Biliary strictures. Gastrointest Endosc. 2009;69:1236-43.

88. Saab S, Hernandez JC, Chi AC, Tong. Spontaneous Bacterial Peritonitis Prophylaxis

Improves Morbidity and Mortality: A Meta-Analysis. Am J Gastroenterol 2009;104:993-

1001.

89. Saab S, Ham M, Stone M, Tong M. Decision-Analysis Model on Hepatitis B Prophylaxis

in Liver Transplant Recipients. Liver Transpl 2009;15:413-20.

90. Kanwal F, Gralnek IM, Hays RD, Zeringue A, Durazo F, Han SB, Saab S, Bolus R,

Spiegel BMR. Health-related quality of life predicts mortality in patients with advanced

chronic liver disease. Clin Gastroenterol Hepatol. 2009;7:793-9.

91. Saab S, Yeganeh M, Nguyen K, Durazo F, Han S, Yersiz H, Farmer DG, Goldstein LI,

Tong MJ, Busuttil RW. Recurrence of Hepatocellular Carcinoma and Hepatitis B

Reinfection in HBsAg Positive Patients after Liver Transplantation. Liver Transpl

2009;15:1525-34.

92. Yeganeh M, Finn RS, Saab S. Apparent remission of a solitary metastatic pulmonary

lesion in a liver transplant recipient treated with sorafenib. Am J Transplant.

2009;9:2851-4.

93. Tabibian JH, Asham EH, Han S, Saab S, Tong MJ, Goldstein L, Busuttil RW, Durazo

FA. Endoscopic treatment of postorthotopic liver transplantation anastomotic biliary

Saab 39

strictures with maximal stent therapy (with video). Gastrointest Endosc. 2010;71:505-

512.

94. Saab S, Waterman B, Chi AC, Tong MJ. Comparison of Different Immunoprophylaxis

Regimens after Liver Transplantation with Hepatitis B Core Antibody Positive Donors: A

Systematic Review. Liver Transpl 2010;16:300-307. With accompanying editorial.

95. Tong MJ, Hsu L, Hsien C, Kao J-H, Durazo FA, Saab S, Blatt LM. A comparison of

hepatitis b viral markers of patients in different clinical stages of chronic infection.

Hepatol Int. 2010;4:516-22.

96. Saab S, Hunt D, Stone MA, McClune A, Tong MJ. Timing of Hepatitis C Antiviral

Therapy Pre and Post Liver Transplantation: A Decision Analysis Model. Liver Transpl.

2010;16:748-59: 16:748-59 With accompanying editorial.

97. Duffy JP, Kao K, Ko CY, Farmer DG, McDiarmid SV, Hong JC, Venick RS, Feist S,

Goldstein L, Saab S, Hiatt JR, Busuttil RW. Long-term patient outcome and quality of

life after liver transplantation: analysis of 20-year survivors. Ann Surg. 2010;252:652-61

98. Saab S, McTigue M, Finn R, Busuttil RW. Sorafenib as adjuvant therapy for high risk

Hepatocellular Carcinoma in Liver Transplant Recipients: Feasibility and Efficacy. Exp

Clin Transplant. 2010 Dec;8(4):307-13

99. Foster F, Budoff, MJ, Saab S, Ahmadi N Gordon C, Guerci ID. Atorvastatin and

Antioxidants for the Treatment of Nonalcoholic Fatty Liver Disease: The St Francis

Heart Study Randomized Clinical Trial. Am J Gastroenterol. 2011 Jan;106(1):71-7

100. Han SH, Durazo FA, Saab S, Tong MJ. A Proposed, Evidence-based Approach to the

Treatment of Chronic Hepatitis B. J Clin Gastroenterol. 2011;45:259-66.

101. Saab S, Desai S, Tsaoi D, Durazo F, Han SH, McClune A, Holt C, Farmer D, Goldstein

L, Busuttil RW. Post-Transplantation Hepatitis B Prophylaxis with Combination Oral

Nucleoside and Nucleotide Analogue Therapy. Am J Transplant. 2011;11:511-7.

102. Saab S, Bownick H, Ayoub N, Durazo F, Han SH, Farmer D, Hong J, Busuttil RW.

Differences in Health Related Quality of Life Scores after Orthotopic Liver Transplant

with Respect to Selected Socioeconomic Factors. Liver Transpl. 2011;17(5):580-90

103. Saab S, Ng V, Landaverde C, Lee, SJ, Comulada S, Arevalo J, Durazo F, Han SH,

Younossi Z, Busuttil RW. Development of a disease specific questionnaire to measure

health related quality of life in liver transplant recipients. Liver Transpl. 2011;17:567-79

104. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C Virus Infection in the

United States. An Estimated of the True Prevalence. Liver Int. 2011;31:1090-101.

105. Saab S, Ng V, Landaverde C, Lee, SJ, Comulada S, Arevalo J, Durazo F, Han SH,

Younossi Z, Busuttil RW. Development of a disease specific questionnaire to measure

health related quality of life in liver transplant recipients. Liver Transpl 2011;17:567-79.

106. Wertheim J, Kupiec-Weglinski J, Petrowsky H, Saab S, Busuttil, RW. Major challenges

limiting liver transplantation in the United States. Am J Transplant 2011;11:1773-84.

107. Hong JC, Jones CM, Duffy JP, Petrowsky H, Farmer DG, French S, Finn R, Durazo FA,

Saab S, Tong MJ, Hiatt JR, Busuttil RW. Comparative analysis of resection and liver

transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a

single center. Arch Surg. 2011;146:683-9.

108. Han SH, Durazo FA, Saab S, Tong MJ A proposed, evidence-based approach to the

treatment of chronic Hepatitis B. J Clin Gastroenterol. 2011;45:259-66.

109. McCombs JS, Yuan Y, Shin J, Saab S. Economic burden associated with patients

diagnosed with hepatitis C. Clin Ther. 2011;33:1268-80.

http://www.ncbi.nlm.nih.gov/pubmed/?term=Saab+S%2C+McTigue+M%2C+Finn+R%2C+Busuttil+RW.+Sorafenib+as+adjuvant+therapy+for+high+risk+Hepatocellular+Carcinoma+in+Liver+Transplant+Recipients%3A+Feasibility+and+Efficacy.+Exp+Clinl+Transplant

http://www.ncbi.nlm.nih.gov/pubmed/?term=Saab+S%2C+McTigue+M%2C+Finn+R%2C+Busuttil+RW.+Sorafenib+as+adjuvant+therapy+for+high+risk+Hepatocellular+Carcinoma+in+Liver+Transplant+Recipients%3A+Feasibility+and+Efficacy.+Exp+Clinl+Transplant

http://www.ncbi.nlm.nih.gov/pubmed/?term=Han+SH%2C+Durazo+FA%2C+Saab+S%2C+Tong+MJ.+A+Proposed%2C+Evidence-based+Approach+to+the+Treatment+of+Chronic+Hepatitis+B.+J+Clin+Gastroenterol

Saab 40

110. Chavalitdhamrong D, Jensen DM, Singh B, Kovacs TO, Han SH, Durazo F, Saab S,

Gornbein JA. Capsule Endoscopy Is Not Accurate as Esophagogastroduodenoscopy in

Screening Cirrhotic Patients for Varices. Clin Gastroenterol Hepatol. 2012;10:254-8.

111. Levitsky J, Fiel MI, Norvell JP, Wang E, Watt KD, Curry MP, Tewani S, McCashland

TM, Hoteit MA, Shaked A, Saab S, Chi AC, Tien A, Schiano TD. Risk for Immune-

Mediated Graft Dysfunction in Liver Transplant Recipients with Recurrent HCV

Infection Treated with Pegylated Interferon. Gastroenterology. 2012;142:1132-1139.

112. Everson GT, Terrault NA, Lok AS, Rodrigo DR, Brown RS Jr, Saab S, Shiffman ML,

Al-Osaimi AM, Kulik LM, Gillespie BW, Everhart JE; and the A2ALL Study Group. A

Randomized Controlled Trial of Pretransplant Antiviral Therapy to Prevent Recurrence

of Hepatitis C after Liver Transplantation. Hepatology. 2013; 57:1752-62.

113. Nadim MK, Sung RS, Davis CL, Andreoni KA, Biggins SW, Danovitch GM, Feng S,

Friedewald JJ, Hong JC, Kellum JA, Kim WR, Lake JR, Melton LB, Pomfret EA, Saab

S, Genyk YS. Simultaneous Liver-Kidney Transplantation Summit: Current State and

Future Directions. Am J Transplant. 2012; 12:2901-8.

114. Rubin J, Ayoub N, Kaldas F, Saab S. Management of Recurrent Hepatocellular

Carcinoma in Liver Transplant Recipients: A Systematic Review. Exp Clinl Transplant.

2012;10:531-43.

115. Saab S, Choi YM, Rahal H, Li K, Tong M. Trends in Viral Hepatitis Cost-Effectiveness

Studies. Am J Managed Care. 2012;18:790-8.

116. McCombs JS, Yuan Y, Shin J, Saab S. Impact of Drug Therapy Adherence in Patients

with Hepatitis C. Am J Pharmacy Benefits 2012;4 [Special Issue]:SP19-SP27.

117. Sood A, Cox GA, McWilliams JP, Wang HL, Saab S. Patients with Nodular

Regenerative Hyperplasia Should be Considered for Hepatocellular Carcinoma

Screening. Hepatology Research. 2014;44:689-93.

118. Matsuda T, Tonnu-Mihara I, Yuan Y, Hines P, Saab S, Italien GJ, McCombs J. External

validation of the risk-prediction model for hepatocellular carcinoma [hcc] from the reveal

HCV study. Value in Health. 2013;16:A12.

119. Campsen J, Zimmerman M, Trotter J, Hong J, Freise C, Brown R, Cameron A, Ghobrial

M, Kam I, Busuttil R, Saab S, Holt C, Emond J, Stiles J, Lukose T, Chang M, Klintmalm

G. Liver transplantation for hepatitis B liver disease and concomitant hepatocellular

carcinoma in the United States with hepatitis B immunoglobulin and

nucleoside/nucleotide analogues. Liver Transpl. 2013; 19:1020-9.

120. Wai H, Stepanova M, Saab S, Erario M, Srishord M, Younossi ZM. The Inpatient

Economic and Mortality Assessment for Liver Transplantation: A Nationwide Study of

the United States Data from 2005 to 2009. Transplantation. 2014. 15;97:98-103

121. Saab S, Mallam D, Cox GA II, Tong MJ. Impact of Coffee on Liver Diseases: A

Systematic Review. Liver International. 2014;34:495-504.

122. Zhou K, Fergusson J, Bau SN, Saab S. Viral Breakthrough is Associated with Resistance

using Direct Acting Agents in Patients Treated for Chronic Hepatitis C Infection. J Clin

Gastroenterol 2014; 48:548-52.

123. Agopian VG, Petrowsky H, Kaldas FM, Zarrinpar A, Farmer DG, Yersiz H, Holt Cm

Harlander-Locke M, Hon JC, Rana AR, Venick R, McDiarmid SV, Goldstein LI, Durazo

F, Saab S, Han S, Xia V, Hiatt JR, Busuttil RW. The Evolution of Liver Transplantation

During 3 Decades. Analysis of 5347 Consecutive Liver Transplants at a Single Center.

Annals of Surgery 2013;258:409-21.

124. Campsen J, Zimmerman M, Trotter J, Hong J, Freise C, Brown RS Jr, Cameron A,

GhobrialM, Kam I, Busuttil R, Saab S, Holt C, Emond JC, Stiles JB, Lukose T, Chang

Saab 41

MS, Klintmalm G. Multicenter review of liver transplant for hepatitis B-related liver

disease: disparities in gender and ethnicity. Clin Transplant 2013; 27:829-37.

125. Wai H, Stepanova M, Saab S, Erario M, Srishord M, Younossi ZM. Inpatient Economic

and Mortality Assessment for Liver Transplantation: A Nationwide Study of the United

States Data from 2005 to 2009. Transplantation. 2014; 97:98-103.

126. McCombs J, Matsuda T, Tonnu-Mihara I, Saab S, Hines P, L'italien G, Juday T, Yuan Y.

The Risk of Long-term Morbidity and Mortality in Patients With Chronic Hepatitis C:

Results From an Analysis of Data From a Department of Veterans Affairs Clinical

Registry. JAMA Intern Med. 2014;174:204-12.

127. Saab S, Lalezari D, Alper T, Pruthi P, Tong MJ. The Impact of Obesity on Patient

Survival in Liver Transplant Recipients: A Meta-Analysis. Liver Int. 2013 Dec 8. [Epub

ahead of print].

128. Terrault NA, Stravitz RT, Lok ASF, Everson GT, Brown Jr RS, Kulik LM, Olthoff KM,

Saab S, Adeyi O, Argo CK, Everhart JE, Rodrigo DR, A2ALL Study Group. Hepatitis C

disease severity in living versus deceased donor liver transplant recipients: An extended

observation study. Hepatology 2014; 59:1311-1319.

129. Sundaram V, May FP, Manne V, Saab S. Effects of Clostridium difficile Infection in

Patients with Alcoholic Hepatitis. Clin Gastroenterol Hepatol. 2014 Oct;12(10):1745-

52.e2

130. Saab S, Manne V, Bau S, Reynolds JA, Allen R, Goldstein L, Durazo F, El-Kabany M,

Han S, Busuttil RW. Boceprevir in Liver Transplant Recipients. Liver Int. 2014.

131. Saab S, Manne V Akhtar E. Cirrhosis Regression in Hepatitis C Patients with Sustained

Virologic Response after Anti-Viral therapy: A Meta-analysis. Liver International 2014

132. Saab S, Gordon SC, Park H, Ahmed A, Younossi ZM. A decision analytic Markov

model to evaluate the health outcomes of sofosbuvir for previously untreated patients and

those without treatment options with chronic hepatitis C virus. Alimentary Pharmacol

Therapy 2014;40:657-75.

133. Saab S, Manne V, Bui V, Sundaram. Cumulative Radiation Exposure in Liver Transplant

Candidates and Patients Transplanted with Hepatocellular Carcinoma. J Liv Dis

Transplant 2014

134. Choi G, Lee KG, Wu C, Saab S. Kidney Transplantation Threshold in Patients with

Hepatitis C: A Decision Analysis Model. Transplantation 2014

135. Stepanova M, Wai H, Saab S, Mishra A, Venkatesan C, Younossi ZM. The Portrait of

an Adult Liver Transplant Recipient in the United States From 1987 to 2013. JAMA

Intern Med. 2014;174:1407-9.

136. Younossi ZM, Stepanova M, Saab S, Kalwaney S, Clement S, Henry L, Frost S, Hunt S.

The impact of type 2 diabetes and obesity on the long-term outcomes of more than

85,000 liver transplant recipients in the US. Aliment Pharmacol Ther. 2014;40:686-94.

137. Curry MP, Forns X, Chung RT, Terrault NA, Brown R Jr, Fenkel JM, Gordon F, O'Leary

J,Kuo A, Schiano T, Everson G, Schiff E, Befeler A, Gane E, Saab S, et al. Sofosbuvir

and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-

label study. Gastroenterology. 2015;148:100-107.

138. Lee EW, Saab S, Gomes AS, Busuttil R, McWilliams J, Durazo F, Han SH, Goldstein L,

Tafti BA, Moriarty J, Loh CT, Kee ST. Coil-Assisted Retrograde Transvenous

Obliteration (CARTO) for the Treatment of Portal Hypertensive Variceal Bleeding:

Preliminary Results. Clin Transl Gastroenterol. 2014;5:e61. doi: 10.1038/ctg.2014.12.

https://www.ncbi.nlm.nih.gov/pubmed/25261839



http://www.ncbi.nlm.nih.gov/pubmed/25273155



Saab 42

139. Stepanova M, Wai H, Saab S, Mishra A, Venkatesan C, Younossi Z. The outcomes of

adult liver transplants in the united states from 1987 to 2013. Liver Int. 2015;358):2036-

41.

140. Younossi Z, Stepanova M, Saab S, Trimble G, Mishra A, Henry L. The association of

hepatitis C virus infection and post-liver transplant diabetes: data from 17,000 HCV-

infected transplant recipients. Aliment Pharmacol Ther. 2015;41:209-17.

141. Al-hamoudi W, Elsiesy H, Bendahmash A, Al-masri N, Ali S, Allam N, Al Sofayan M,

Al Bahili H, Al Sebayel, Dieter Broering M, Saab S, Abaalkhail F. Liver transplantation

for hepatitis B virus: Decreasing indication and changing trends. W J Gastroenterol

2015;21: 8140-7.

142. Saab S, Greenberg A, Li E, Bau SN, Durazo F, El-Kabany M, Han S, Busuttil RW.

Sofosbuvir and Simeprevir is Effective for Recurrent Hepatitis C in Liver Transplant

Recipients. Liver International 2015;35:2442-7. With accompanying editorial.

143. Saab S, Alper T, Sernas E, Pruthi P, Alper MA, Sundaram V. Hospitalized Patients with

Cirrhosis should be Screened for Clostridium Difficile Colitis. Dig Dis Sciences

2015;60:3124-9.

144. Saab S, Jimenez M, Fong T, Wu C, El Kabany M, Tong MJ. Timing of Antiviral

Therapy in Liver Transplant Candidates listed for Hepatitis C and Hepatocellular

Carcinoma. Exp Clin Transpl 2016;14: 66-71.

145. Al-Hamoudi W, Elsiesy H, Bendahmash A, Al-Masri N, Ali S, Allam N, Al Sofayan M,

Al Bahili H, Al Sebayel M, Broering D, Saab S, Abaalkhail F. Liver transplantation for

hepatitis B virus: Decreasing indication and changing trends. World J Gastroenterol.

2015;21:8140-7

146. Saab S, Jimenez M, Bau S, Goo T, Zhao D, Durazo F, Han S, El Kabany M, Kaldas F,

Tong MJ, Busuttil RW. Treating Fibrosing Cholestatic Hepatitis C with Sofosbuvir and

Ribavirin: A Matched Analysis. Clin Transplant. 2015; 29: 813-9.

147. Bonham CA, Saab S, Younossi ZM, Ahmed A. HCV Infection is Associated with Lower

Survival in Simultaneous Liver Kidney Transplant Recipients in the U.S. Perumpail RB,

Wong RJ, Scandling JD, Ha LD, Todo T. Clin Transplant. 2015;29:920-6.

148. Kuei A, Saab S, Cho SK, Kee ST, Lee EW. Effects of Yttrium-90 selective internal

radiation therapy on non-conventional liver tumors. World J Gastroenterol.

2015;21:8271-83.

149. Younossi ZM, Stepanova M, Saab S, Ahmed A, Lam B, Srishord M, Venkatesan C, Wai

H, Henry L. The impact of viral hepatitis-related hepatocellular carcinoma to post-

transplant outcomes. J Viral Hepat. 2016: 23: 53-61.

150. Saab S, Suraweera D, Au J, Saab E, Alper T, Tong MJ. Probiotics are Helpful in Hepatic

Encephalopathy: A Meta-Analysis of Randomized Trials. Liver Int 2016;36:986-93.

151. Sheen V, Nguyen H, Jimenez, M, Agopian V, Vangala S, Elashoff D, Saab S. Routine

Laboratory Blood Tests May Diagnose Significant Fibrosis in Liver Transplant

Recipients with Chronic Hepatitis C: a 10-Year Experience. J Clin Translational

Hepatol 2016;4:20-5.

152. Lu NT, Crespi CM, Liu NM, Vu JQ, Ahmadieh Y, Wu S, Lin S, McClune A, Durazo F,

Saab S, Han S, Neiman DC, Beaven S, French SW. A Phase I Dose Escalation Study

Demonstrates Quercetin Safety and Explores Potential for Bioflavonoid Antivirals in

Patients with Chronic Hepatitis C. Phytother Res. 2016; 30: 160-8.

153. Stepanova M, Henry L, Garg R, Kalwaney S, Saab S, Younossi Z. Risk of de novo post-

transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic

steatohepatitis. BMC Gastroenterol. 2015;15:175.






















Saab 43

154. Saab S; Park SH; Mizokami M; Omata M; Mangia A; Eggleton E; Zhu Y et al. Safety

and Efficacy of Ledipasvir/Sofosbuvir for the Treatment of Genotype 1 Hepatitis C in

Subjects Aged 65 Years or Older. Hepatology 2016;63:1112-9.

155. Tonnu-Mihara I, Matsuda T, McCombs, J, Saab S, Hines P, L’Italien G, Juday T, Yuan

Y. Five Laboratory Tests Predict Patient Risk and Treatment Response in Hepatitis C:

Veterans Affairs Data from 1999-2010. Universal Journal of Medical Science 2016;4:10-

20.

156. Goring SM, Gustafson P, Liu Y, Saab S, Cline SK, Platt RW. Disconnected by design:

Analytic approach in treatment networks having no common comparator. Research

Synthesis Methods 2016. DOI: 10.1002/jrsm.1204.

157. McCombs J, Matsuda T, Tonnu-Mihara I, Saab S, Hines P, L’Italien G, Kalsekar A,

Yuan Y. Using the Fib-4 Score to Monitor Morbidity and Mortality Risk in Chronic

Hepatitis C Patients. J Virol Retrovirol 2016; 2: 1-10.

158. Duminda S, Jimenez M, Viramontes M, Naadir J, Grotts J, Elashoff D, Lee E, Saab S.

Age-Related Morbidity and Mortality after Transjugular Intrahepatic Portosystemic

Shunts. J Clin Gastroenterol 2017; 51: 360-363.

159. Molski C, Sarria EE, Mattiello R, Saab S, Medeiros R, Brandão A. Cultural validation of

the post-Liver transplant quality of life (pLTQ) questionnaire for the Brazilian

population. Ann Hepatol 2016;15:377-385.

160. Saab S, Rheem J, Jimenez M, Bau S, Choi G, Durazo F, El Kabany M, Han S, Farid A,

Jamal N, Grotts J, Elashoff D, Busuttil RW. Curing Hepatitis C in Liver Transplant

Recipients Is Associated with Changes in Immunosuppressant Use. J Clin Transl

Hepatol. 2016;4:32-8.

161. Saab S, Parisé H, Virabhak S, Wang A, Marx SE, Sanchez Gonzalez Y, Misurski D,

Johnson S. Cost-effectiveness of currently recommended direct-acting antiviral

treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the United

States. J Med Econ. 2016;8:795-805.

162. Saab S, Jimenez M, Fong T, Wu C, Bau S, Grotts J, Elashoff D. Accessibility to Oral

Antiviral Therapy for Patients with Chronic Hepatitis C in the United States. J Clin

Transl Hepatol. 2016;4:76-82.

163. Elrazek AE, Amer M, Hawary B, Salah A, Bhagavathula AS, Al Boraie M, Saab S.

Prediction of HCV vertical transmission: What are factors should be optimized using data

mining computational analysis. Liver Int. 2017; 37: 529-533.

164. Saab S, Jimenez M, Bau S, Choi G, Durazo F, El Kabany M, Han SB, Busuttil RW. Use

of Sofosbuvir- Based Treatment of Chronic Hepatitis C in Liver Transplant Recipients on

Hemodialysis. J Clin Gastroenterol 2016; 51: 167-173.

165. Koenig A, Stepanova M, Saab S, Ahmed A, Wong R, Younossi ZM. Long-term

outcomes of lung transplant recipients with hepatitis C infection: a retrospective study of

the U.S. transplant registry. Aliment Pharmacol Ther. 2016; 44: 271-8.

166. Younossi ZM, Park H, Gordon SC, Ferguson JR, Ahmed A, Dieterich D, Saab S. Real-

world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C. Am

J Manag Care. 2016 May;22(6 Spec No.):SP205-1.

167. Saab S, Virabhak S, Parise H, Johnson S, Wang A, Misurski D, Gonzalez YS, Juday T.

Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients

Coinfected with Human Immunodeficiency Virus in the United States. Adv Ther

2016;33:1-42.

168. Young K, Aguilar M, Gish R, Younossi Z, Saab S, Bhuket T, Liu B, Ahmed A, Wong

RJ. Lower Rates of Receiving Model for End-Stage Liver Disease Exception and Longer

















Saab 44

Time to Transplant Among Non-Alcoholic Steatohepatitis Hepatocellular Carcinoma.

Liver Transpl. 2016;22:1356-66.

169. Kuei A, Lee EW, Saab S, Busuttil RW, Durazo F, Han SH, ElKabany M, McWilliams

JP, Kee ST. Inpatient Cost Assessment of Transjugular Intrahepatic Portosystemic Shunt

in the USA from 2001 to 2012. Dig Dis Sci. 2016;61: 2838-2846.

170. Lee EW, Kuei A, Saab S, Busuttil RW, Durazo F, Han SH, El-Kabany MM, McWilliams

JP, Kee ST. Nationwide trends and predictors of inpatient mortality in 83884 transjugular

intrahepatic portosystemic shunt. World J Gastroenterol. 2016;22:5780-9.

171. Younossi ZM, Park H, Dieterich D, Saab S, Ahmed A, Gordon SC. Assessment of Cost

of Innovation versus the Value of Health Gains Associated with Treatment of Chronic

Hepatitis C in the United States: The Quality-Adjusted Cost of Care. Medicine.

2016;95(41):e5048.

172. May FP, Rolston VS, Tapper EB, Lakshmanan A, Saab S, Sundaram V. The impact of

race and ethnicity on mortality and healthcare utilization in alcoholic hepatitis: a cross-

sectional study. BMC Gastroenterol. 2016; 16(1): 129.

173. Younossi ZM, Park H, Dieterich D, Saab S, Ahmed A, Gordon SC. The Value of Cure

Associated with Treating Treatment-naive Chronic Hepatitis C Genotype 1: Are the New

All Oral Regimens Good Value to Society? Liver Int. 2017;37:662-668.

174. Saab S, Konyn PG, Viramontes MR, Jimenez MA, Grotts, JF, Hamidzadah W, Dang VP,

Esmailzadeh NL, Choi G, Durazo FA, El-Kabany MM, Han SHB, Tong MJ. Limited

knowledge of acetaminophen in patients with liver disease. Journal of Clinical and

Translational Hepatology 2016; 4:281-287.

175. Younossi ZM, Gordon SC, Ahmed A, Dieterich D, Saab S, Beckerman R. Treating

Medicaid Patients with Hepatitis C: Clinical and Economic Impact. A J Managed Care.

2017;23:294-299.

176. Nguyen K, Jimenez M, Moghadam N, Wu C, Farid A, Grotts J, Elashoff D, Choi G,

Durazo FA, El-Kabany MM, Han SHB, Saab S. Decrease of Alpha-Fetoprotein in

Patients with Cirrhosis Treated with Direct Acting Agents. J Clin Transl Hepatol

2017;5:43-49.

177. Patel AA, Walling AM, May FP, Saab S, Wenger N. Palliative Care and Healthcare

Utilization for Patients with End-Stage Liver Disease at the End of Life. Clin

Gastroenterol Hepatol. 2017;15:1612-1619.

178. Lin TY, Shekar AO, Li N, Yeh MW, Saab S, Wilson M, Leung AM Incidence of

Abnormal Liver Biochemical Tests in Hyperthyroidism. Clin Endocrinol (Oxf). 2017;

86:755-759.

179. Ahmed A, Gonzalez SA, Cholankeril G, Perumpail RB, McGinnis J, Saab S, Beckerman

R, Younossi ZM. Treatment of Patients Waitlisted for Liver Transplant with an All-Oral

DAAs is a Cost-Effective Treatment Strategy in the United States. Hepatology

2017;66:46-56.

180. Younossi Z, Gordon SC, Ahmed A, Dieterich D, Saab S, Beckerman R. Treating

Medicaid patients with hepatitis C: clinical and economic impact. Am J Manag Care.

2017;23:107-112.

181. Saab S, Rheem J, Jimenez MA, Fong TM, Mai MM, Kachardoorian CA, Esmilzadeh

NL, Bau SN, Kang S, Ramirez SD, Grotts, Choi G, Durazo FA, El-Kabany MM, Han

SHB, Busuttil RW. Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavirin in

Liver Transplant Recipients with Hepatitis C. J Clin Transl Hepatol 2017;5:101-108.

182. Saab S, Phan J, Jimenez M, Grotts J, Walters L, Hathaway K, Patel K, Lankarani A,

Herman M, Holloman D, Nieto J. Endoscopic Ultrasound Liver Biopsies Accurately






















Saab 45

Predict the Presence of Fibrosis in Patients with Fatty Liver. Clin Gastroenterol Hepatol

2017;15:1477-1478.

183. Elrazek A, Saab S, Foad M, Elgohary EA, Sallam MM, Nawara A, Ismael A, et al.

Ongoing transmission of HCV: Should cesarean section be justified? Data mining

discovery. J Transl Int Med. 2017;5:27-33.

184. Stepanova M, Clement S, Wong R, Saab S, Ahmed A, Younossi ZM. Patients with

Diabetes and Chronic Liver Disease are at Increased Risk for Overall Mortality: A

Population Study from the United States. Clinical Diabetes 2017;35:79-83.

185. Aby E, Jimenez MA, Grotts JF, Agopian V French SW, Busuttil RW, Saab S.

Diminishing Role of Liver Biopsy for Hepatitis C in Liver Transplant Recipients. J Clin

Transl Hepatol 2017; 5:197-202.

186. Tavakoli H, Robinson A, Liu B, Bhuket T, Younossi Z, Saab S, Ahmed A, Wong RJ.

Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to

Receive Surveillance for Hepatocellular Carcinoma. Dig Dis Sci. 2017;62:2174-2181.

187. Castrejón M, Chew KW, Javanbakht M, Humphries R, Saab S, Klausner JD.

Implementation of a Large System-Wide Hepatitis C Virus Screening and Linkage to

Care Program for Baby Boomers. Open Forum Infect Dis. 2017;4(3):ofx109. doi:

10.1093/ofid/ofx109.

188. Saab S, Sikavi C, Jimenez M, Viramontes M, Allen R, Challita Y, Mai M, Esmailzadeh

N, Grotts J, Choi G, Durazo F, El-Kabany M, Han SH, Moreno E. Clinical Food

Addiction Is Not Associated with Development of Metabolic Complications in Liver

Transplant Recipients. J Clin Transl Hepatol. 2017;5:335-342.

189. Saab S, Viramontes, MR, Chalifoux SL, Craw CJ, Ramirez SD, Bau SN, Arevalo DG,

Saab EG, Saab CM, Craw CS, Estafanous A, Messiah R, Messiah W, El Kabany M.

Hepatitis C Virus Prevalence in Egyptian-Americans in Southern California. J Clin


190. Nieto J, Khaleel H, Challita Y, Jimenez M, Baron TH, Walters L, Hathaway K, Patel K,

Lankarani A, Herman M, Holloman, D, Saab S. Endoscopic Ultrasound guided Fine

Needle Core Liver Biopsy using a Novel 19 Gauge Needle with Modified One Pass One

Actuation Wet Suction Technique. Gastrointestinal Endoscopy. 2018;87:469-475

191. Abaalkhail F, Elsiesy H, Elbeshbeshy H, Shawkat M, Yousif S, Ullah W, Alabbad S, Al-

Jedai A, Ajlan A, Broering D, Saab S, Al Sebayel M, Al-Hamoudi W. Treatment of

Patients With Hepatitis C Virus infection (Genotype 4) With Ledipasvir-Sofosbuvir in

the Liver Transplant Setting. Transplantation. 2017;101:2739-2745

192. Sikavi C, Chen PH, Lee A, Saab EG, Choi G, Saab S. Hepatitis C and Human

immunodeficiency Virus Co-Infection in the Era of Direct-Acting Antiviral Agents: No

Longer A Difficult to Treat Population. Hepatology 2018;67:847-857.

193. Suraweera D, Fanous C, Jimenez M, Tong MJ, Saab S. Risk of Cardiovascular Events in

Patients with Primary Biliary Cholangitis ~ Systematic Review. J Clin Transl Hepatol

2018;6:119-126.

194. Corson M, Moch A, Saab S. Hepatitis C Virus Treatment in Patients with Chronic

Kidney Disease and in Kidney Transplant Recipients. Gastroenterol Hepatol (N Y).

2018;14:280-285.

195. Hanna RM, So N, Kaldas M, Hou J, Arman F, Sangalang M, Yanny B, Selamet U, Saab

S, Nobakht N, Rastogi A. Case Report: Patient with Hepatitis C, p-ANCA, and

Cryoglobulin Antibodies Presenting with Necrotizing Crescentic p-ANCA G

lomerulonephritis. Case Rep Nephrol Dial 2018;8:161-170













Saab 46

196. Saab S, Mehta D , Hudgens S, Grunow N, Bao Y , Brett Pinsky. Effect of

ombitasvir/paritaprevir/ritonavir + dasabuvir regimen on health related quality of life for

patients with hepatitis C. Liver International 2018;38(8):1377-1394

197. Saab S, Abbey B, Challita Y, Adeniyi A, Aziz A, Choi G, Durazo F, El-Kabany M, Han

SH, Busuttil RW. Impact of Sustained Viral Response with Direct Acting Agents on

Glycemic Control and Renal Function in Liver Transplant Recipients. Experimental Clin

Transplant 2018;16:419-424

198. Chirikov VV, Marx SE, Manthena SR, Strezewski JP, Saab S. Development of a

Comprehensive Dataset of Hepatitis C Patients and Examination of Disease

Epidemiology in the United States, 2013–2016. Adv Ther 2108;35:1087-1102.

199. Yanny B, Saab S, Durazo F, Latt N, Mitry A, Mikhail MM, Hanna RM, Aziz A, Sahota

A. Eight-Week Hepatitis C Treatment with New Direct Acting Antivirals Has a Better

Safety Profile While Being Effective in the Treatment-Naïve Geriatric Population

Without Liver Cirrhosis and Hepatitis C Virus-RNA < 6 Million IU/mL. Dig Dis Sci.

2018;63:3480-3486.

200. Saab S, Saggi SS, Akbar M, Choi G. Presumed Consent: A Potential Tool for Countries

Experiencing an Organ Donation Crisis. Dig Dis Sci. 2018; 64:1346-1355. With

accompanying editorial.

201. Le LB, Rahal HK, Viramontes MR, Meneses KG, Dong TS, Saab S. Patient Satisfaction

and Health Care Utilization using Telemedicine in Liver Transplant Recipients. Dig Dis

Sci. 2018;64:1150-1157.

202. Saab S, Challita. Y, Kahaleh M, Holloman D, Hathaway K, Nieto J. Case Series Review

of the Safety and Efficacy of Endoscopic Ultrasound Guided Splenic Mass Core Biopsy.

Clinical Endoscopy 2018;51:600-601.

203. Saab S, Ahn T, McDaniel T, Yanny B, Tong, M. Economic Comparison of Serologic and

Molecular Screening Strategies for Hepatitis C Virus. Gastroenterol Hepatol (N Y).

2018;14:459-462.

204. Yanny B, Latt N, Saab S, Han S, Choi G, Kramer J, Sahota A. Risk of Hepatitis B Virus

Reactivation Among Patients Treated with Ledipasvir-Sofosbuvir for Hepatitis C Virus

Infection. J Clin Gastroenterology 2018;52:908-912.

205. Phan J, Ng V, Sheinbaum A, French S, Choi G, El Kabany M, Durazo F, Saab S, Tong

M, Busuttil R, Han SH. Hyperlipidemia and Nonalcoholic Steatohepatitis Predispose to

Hepatocellular Carcinoma Development Without Cirrhosis. J Clin Gastroenterol.

2018;53:309-313.

206. Lee EW, Saab S, Kaldas F, Fletcher S, Busuttil RW, Durazo F, McWilliams JP,

DiNorcia J 3rd, Padia SA, Kee ST. Coil-Assisted Retrograde Transvenous Obliteration

(CARTO): An Alternative Treatment Option for Refractory Hepatic Encephalopathy. Am

J Gastroenterol. 2018;113:1187-1196.

207. Saab S, Kardashian A, Saggi S, Choi G, Agopian A, Tong MJ, Use of Hepatitis C

Positive Grafts in Hepatitis C Negative Liver Transplant Recipients is Cost-Effective.

Clinical Transplantation 2018;32:e13383.

208. Saab S, Le Long, Saggi S, Sundaram V, Tong M. Towards the Elimination of Hepatitis C

in the United States. Hepatology 2018; 67:2449-2459.

209. Saab S, Youssef C, Chen PH, Jimenez MA, Lee AD, Saab EG, Ahn T, Choi G, Durazo

F, El-Kabany M, Han SH, Grotts J, Agopian VG, Busuttil RW. The Elimination of

Hepatitis C in Liver Transplant Recipients. J Clin Transl Hepatol. 2018;28;6:247-250.

210. Reardon LC, DePasquale EC, Tarabay J, Cruz D, Laks H, Biniwale RM, Busuttil RW,

Kaldas FM, Saab S, Venick RS, Lin JP, Nsair A, Deng MC, Ardehali A, Caderias M,








Saab 47

Iygengar A, Aboulhosn JA. Heart and heart-liver transplantation in adults with failing

Fontan physiology. Clin Transplant. 2018;32(8):e13329.

211. Sue MJ, Lee EW, Saab S, McWilliams JP, Durazo F, El-Kabany M, Kaldas F, Busuttil

RW, Kee ST. Transjugular Liver Biopsy: Safe Even in Patients With Severe

Coagulopathies and Multiple Biopsies. Clin Transl Gastroenterol. 2019;10(7):e00063.

212. Aby E, Phan J. Troung E. Grotts J, Saab S. Inadequate Hepatocellular Carcinoma

Screening in patients with Non-Alcoholic Steatohepatitis Cirrhosis. J Clin Gastroenterol

2018;53:142-146.

213. Aby E, Lee E, Saggi SS, Viramntes MR, Grottss JF, Agopian A, Busuttil RW, Saab S

Pre-Transplant Sarcopenia in Patients with NASH Cirrhosis does not impact re-

hospitalization or mortality. J Clin Gastroenterology 2018;53(9):680-685.

214. Saab S, Song D. Challita YP, Zhou TX, Saab EG, Viramontes MR, Choi G, Durazo FA,

Han SB, El Kabany MM, Jackson NJ, Busuttil RW. Long-term Outcomes with Oral

Therapy in Liver Transplant Recipients with Hepatitis B. Clin Transplant 2019 (in press).

215. Benitez TM, Fernando SM, Amini C, Saab S. Geographically Focused Collocated

Hepatitis C Screening and Treatment in Los Angeles’s Skid Row. Dig Dis Sci 2020 (in

press).

216. Fong T, Wu C, Wu S, Saab S. Hepatitis B Surface Antigen Levels Predict Spontaneous

Hepatitis B Surface Antigen Seroconversion in Inactive Hepatitis B Carriers. J Clin

Gastroenterology 2020 (in press).

217. Lee EW, Lee AE, Saab S, Kee ST. Retrograde Transvenous Obliteration (RTO): A New

Treatment Option for Hepatic Encephalopathy. Dig Dis Sci. 2020 (in press)

218. Hirode G, Saab S, Wong RJ. Trends in the Burden of Chronic Liver Disease Among

Hospitalized US Adults. JAMA Netw Open. 2020;3(4):e201997

219. Nieto J, Dawod E, Deshmukh A, Penn E, Adler D, Saab S. EUS-Guided Fine Needle

Core Liver Biopsy with a Modified 1-Pass 1-Actuation Wet Suction Technique:

Comparing Two Types of EUS Core Needles. Endoscopy International Open. 2020 (in

press).

220. Hameed B, Veracruz N, Saab S, Wong R. The Association Between Nonalcoholic Fatty

Liver Disease and Risk of Cardiovascular Disease, Stroke, and Extra-Hepatic Cancers. J

Cli Exp Hepatol 2020 (in press).

C. RESEARCH PAPERS - PEER REVIEWED (SUBMITTED) None.

B. RESEARCH PAPERS - PEER REVIEWED (IN PRESS)

RESEARCH PAPERS (NON-PEER REVIEWED) None.

D. RESEARCH PAPERS - NON-PEER REVIEWED None.

E. RESEARCH PAPERS - NON-PEER REVIEWED (IN PRESS) None.

F. RESEARCH PAPERS - NON-PEER REVIEWED (SUBMITTED) None.







Saab 48

BOOK CHAPTERS

1. Saab S, Martin P. Liver and biliary diseases (book review). In: Friedman LS, ed. Print

and media reviews. Gastroenterology 1998;115:505.

2. Saab S, Jutabha R. Approach to the patient with lower gastrointestinal bleeding. In:

Rose BD, ed. UpToDate. Wellesley MA: UpToDate 2000.

3. Saab S, Jutabha R. Etiology of lower gastrointestinal bleeding. In: Rose BD, ed.

UpToDate. Wellesley MA: UpToDate 2000.

4. Saab S, Rojter SE. Cirrhosis. In Encyclopedia of Public Health, ed. L. Breslow. New

York & Detroit: Macmillan Reference USA. 2002. 205-7.

5. Saab S, Han SHB, Martin P. Management of the patient awaiting liver transplantation.

In Practical Manual of Abdominal Organ Transplantation, Manzarbeitia C, ed. Kluwer

Academic/Plenum Publishers. 2002: 27-40.

6. Saab S, Jutabha R. Endoscopic management of lower GI bleeding. In: Wong RCK, Van

Dam J, eds. Handbook of Gastrointestinal Endoscopy. Austin: RG Landes Co: 2004.

7. Saab S, Rosen H. Approach to the Patient with Chronic Hepatitis B and C. In: Atlas of

Gastroenterology. Yamada T, Albers DH, Kaplowitz N, Owyang C, Powell DW, Kalloo

A, eds. Blackwell Publishers 2008.

8. Chang M, Sung H, Saab S. Treating HCV after Liver Transplantation. In Chronic

Hepatitis C Virus: Lessons from the Past Promise for the Future, ed Shiffman ML. New

York: Publisher Springer Science. 2011.

9. Suraweera D, Konyn P, Vu T, Saab S. Epidemiology of Chronic Liver Disease:

Hepatocellular Carcinoma. In Clinical Epidemiology of Chronic Liver Disease. eds: Gish

R and Wong R. Cambridge: Springer. 2018

10. Corson M, Najarian L, Saab S. Management of Ascites. In: Liver Disease: A Clinical

Casebook. eds: Cohen SM and Davitkov P. New York: Publisher Springer Science. 2019.

LETTERS TO THE EDITOR None.

REVIEWS

1. Yao F, Saab S. A practical approach to abnormal liver chemistries. Practical


2. Saab S, Martin P. Hepatitis C: a practical approach to diagnosis and management.

Family Practice Recertification 1998;20:21-44.

3. Saab S, Martin P. Medical care of the liver transplant patient (book review). In: Maher

J, ed. Hepatology elsewhere. Hepatology 1998; 27:1449.

4. Saab S, Martin P. The role of consensus interferon for chronic hepatitis C infection.

Current Treatment Options Infect Dis 2000;2:115-9.

5. Saab S, Han SHB, Martin P. Liver transplantation: selection, listing criteria, and pre-

operative management Clin Liv Dis 2000;4:513-532.

6. Han SHB, Saab S, Martin P. Acute viral hepatitis. Curr Treat Options Gastroenterol.

2000;3:481-486.

7. Saab S, Martin P. Update on hepatitis C. Medscape Gastroenterol, 3(1) 2001.

8. Lin R, Saab S. The current status of hepatitis C virus infection. Inter J Art Organs.

2001;24: 838-42.

9. Saab S, Wang V. Recurrent hepatitis C in liver transplant recipients: diagnosis, natural

history and therapeutic options. J Clin Gastroenterol 2003;37:155-163.

10. Chang A, Dixit V, Saab S. Fulminant hepatic failure. Curr Treat Options

Gastroenterol. Curr Treat Options Gastroenterol. 2003;6:473-479

Saab 49

11. Saab S, Busuttil RW. Practical management of hepatitis C in liver transplant recipients.

Minerva Chirurgica 2003;58:479-89.

12. Karson H, Rojter SE, Saab S. Cirrhosis: a preventable medical and public health

concern. Postgrad Med 2004;115:25-30.

13. Wang V, Saab S. Liver transplantation in the era of MELD. Liver International

2004;24:1-8.

14. Kim A, Saab S. Treatment of hepatitis C. Am J Med. 2005;118:808-15.

15. Nieto J, Saab S. Outcomes of liver transplantation using hepatitis B core positive live

grafts: implications for prophylaxis. Current Hepatitis Reports 2006;5:33-39.

16. Dong M, Saab S. Management of Cirrhosis. Disease a Month 2008;54:445-56.

17. Surti B, Chi A, Saab S. Update on Management of Hepatitis B before and after Liver

Transplantation. Current Hepatitis Reports 2008;7:25-32.

18. Nieto J, Saab S. Outcomes of liver transplantation using hepatitis B core positive live grafts:

implications for prophylaxis. 2008 Update. Current Hepatitis Reports 2008;2:268-75.

19. Surti B, Tan J, Saab S. Pregnancy in Liver Transplantation. Liver International 2008;

28:1200-6.

20. Tan J, Surti B, Saab S. Cirrhosis and Pregnancy. Liver Transpl 2008;14:1081-91.

21. Tan J, Saab S. Hepatitis B: Indications for therapy indication. Medscape Gastroenterol, 3

2008.

22. Hunt DR, Saab S. Viral hepatitis in incarcerated adults: a medical and public health concern.

Am J Gastroenterol. 2009;104:1024-31.

23. Landaverde C, Saab S. Optimizing Peg-Interferon and Ribavirin Dosing in Difficult to Treat

Patient Populations. Current Hepatitis Reports 2009, 8:43–51

24. Saab S. Academic Perspectives on Hepatitis C: Treatment Adherence Gastroenterology and

Hepatology 2009. Mar: 5 (3).

25. Dong M, Saab S. Management of Cirrhosis. Gastroenterology and Hepatology

2009;5:191-197.

26. Tan J, Saab S. New Strategies in Hepatitis B Treatment. Medscape Gastroenterol, 2009.

27. Martyak LA, Yeganeh M, Saab S. Hepatitis C and Lymphoproliferative Disorders: From

Mixed Cryoglobulinemia to Non-Hodgkin’s Lymphoma. Clinical Gastroenterology and

Hepatology 2009 2009;7:900-5.

28. Siqueira F, Kelly T, Saab S. Refractory Ascites: Pathogenesis, Clinical Impact and

Management. Gastroenterology and Hepatology 2009;5:1-10.

29. Bownik H, Saab S. Health-Related Quality of Life after Liver Transplantation for Adult

Recipients. Liv Transplant 2009;15:S42-9.

30. Chak E, Saab S. Pegylated Interferon and Ribavirin Dosing Strategies to Enhance

Sustained Virologic Response. Curr Hepat Rep. 2010;9:147-154.

31. Bownik H, Saab S. The Effects of Hepatitis C Recurrence on Health Related Quality of

Life in Liver Transplant Recipients. Liver International. 2010;30:19-30.

32. Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic

Response. Current Hepatitis Reports 2010.9:147-154

33. Movahedi Z, Holt CD, Saab S. Immunosuppression Strategies in Liver Transplantation: A

Primer. Exp Clin Transplant 2010;8:83-90.

34. Desai S, Hong J, Saab S. Cardiovascular Risk Factors Following Orthotopic Liver

Transplantation: Predisposing Factors, Incidence, and Management. Liver International 2010;

30:948-57.

35. Chak E, Saab S. Risk Factors and Incidence of De Novo Malignant in Liver Transplant

Recipients. A Systematic Review. Liver International 2010;30:1247-58.



Saab 50

36. Ng V, Saab S. Clinical Focus -- Management of Hepatitis C in Special Populations:

Understanding and Applying the Evidence. Medscape Gastroenterol (in press).

37. El-Masry M, Puig C, Saab S. Recurrence of Non-Viral Liver Disease after Orthotopic Liver

Transplantation. Liver International 2011;31:291-302.

38. Ng Vivian, Saab S. Effects of a Sustained Viral Response on Outcomes of Patients with

Chronic Hepatitis C. Clin Gastroenterol Hepatol 2011;9:923-30.

39. Khungar V, Saab S. Cirrhosis with Refractory Ascites: Serial Large Volume Paracentesis,

TIPS, or Transplantation? Clin Gastroenterol Hepatol. 2011;931-5.

40. Change M, Saab S. Interferon for Hepatitis B: Which Populations Benefit the Most. Curr

Hepatitis Rep 2011 10:285–291

41. Padua D, Bau S, Saab S. Treating Chronic Hepatitis C Viral Infection: Rethinking Dose

Reduction Strategies for PEG-IFN and Ribavirin in the Setting of New Direct Acting Agents.

Current Hepatitis Reports 2013; Published Online.

42. Yu C, Sharma N, Saab S. Hyponatremia: Clinical Associations, Prognosis and Treatment in

Cirrhosis. Exp Clinl Transplant 2013;11:3-11.

43. Saab S. Hepatitis C in Liver Transplantation. Ann Saudi Med. 2013;33:91-93 (supplement).

44. Saab S, Heber D. Nutrition and Liver Disease in Handbook of Nutrition and Food, Third

Edition-Chapter 51. 2013.

45. Manne V, Saab S. Impact of nutrition and obesity on chronic liver disease. Clin Liver Dis.

2014;18:205-18.

46. Saab S. Hepatic Decompensation. Gastronterology and Hepatology 2007.

47. Landaverde C, Saab S. Evaluation of the potential liver transplant recipient. Liver

International 2008;28:1186-9.

48. Sood A, Castrejón M, Saab S. The Approach to the Patient with HIV and Nodular

Regenerative Hyperplasia W J Hepatol 2014;6:55-63.

49. Younossi ZM, Kanwal F, Saab S, Brown KA, El-Serag HB, Kim WR, Ahmed A,

Kugelmas M, Gordon SC. The Impact of Hepatitis C Burden: An Evidence Based

Approach. Alimentary Pharmacol Therap 2014;39:518-31.

50. Manne V, Sassi K, Allen R, Saab S. Hepatitis C and Work Impairment: A review of

current literature. J Clin Gastroenterol 2014;48:595-9.

51. Klintmalm GB, Saab S, Hong JC, Nashan B. The Role of Mammalian Target of

Rapamycin Inhibitors in the Management of Posttransplant Malignancy. Clin

Transplant. 2014;28:635-48.

52. Manne V, Allen RM, Saab S. Strategies for the prevention of recurrent hepatitis B virus

infection after liver transplantation. Gastroenterol Hepatol (N Y). 2014;10:175-9.

53. Manne V, Akhtar E, Saab S. Cirrhosis Regression in Patients with Viral Hepatitis B and

C: A Systematic Review. J Clin Gastroenterol. 2014 Oct;48(9):e76-84.

54. Saab S, Jackson C, Nieto J, Francois F. Hepatitis C in African-Americans. Am J

Gastroenterol. 2014;109:1576-84

55. Wu T, Morgan TR, Klein AS, Volk ML, Saab S, Sundaram V. Controversies in early

liver transplantation for severe alcoholic hepatitis. Annals of Hepatology 2018;17:759-

768.

56. Yanny B, Konyn P, Najarian LM, Mitry A, Saab S. Management Approaches to

Hepatitis B Virus Vaccination Nonresponse. Gastroenterol Hepatol (N Y). 2019;15:93-

99.

57. Wu T, Konyn PG, Cattaneo AW, Saab S. The New Face of Hepatitis C. Dig Dis Sci.

2019 ;64:1782-1788.

Saab 51

58. Saab S, Brown RW. Management of Thrombocytopenia in Patients with Chronic Liver

Disease. Dig Dis Sci. 2019;64:2757-2768

59. Sikavi C, Najarian L, Saab S. Similar Sustained Virologic Response in Real-World and

Clinical Trial Studies of Hepatitis C/Human Immunodeficiency Virus Co-Infection. Dig

Dis Sci 2018;63:2829-2839

60. Shetty A, Buch A, Saab S. Use of Hepatitis C Positive Liver Dig Dis Sci. 2018;64:1110-

1118

61. Frenette C, Isaacson A, Bargellini I, Saab S, Singal G. A Practical Guideline for

Hepatocellular Carcinoma Screening in Patients at Risk. Mayo Clin Proc Inn Qual Out

2019 ;3:302-310.

62. Yanny B, Winters A, Boutros S, Saab S. Hepatic Encephalopathy Challenges, Burden,

and Diagnostic and Therapeutic Approach. Clin Liver Dis. 2019;23:607-623.

63. Aby ES, Saab S. Frailty, Sarcopenia, and Malnutrition in Cirrhotic Patients. Clin Liver

Dis. 2019;23:589-605.

64. Saab S, Kullar R, Amini C, Grounder P. The Next Frontier: Universal HCV Screening in

pregnant women. American Journal of Obstetrics & Gynecology 2020 (in press).

65. Saab S, Bernstein D, Hassanein T, Kugelmas M, Kwo P. Treatment Options for

Thrombocytopenia in Patients with Chronic Liver Disease Undergoing a Scheduled

Procedure. J Clin Gastroenterol 2020 (in press).

66. Yanny B, Boutros S, Saleh F, Saab S. Liver Transplantation for Alcoholic Hepatitis:

Update. Current Opinion in Gastroenterology. 2020 (in press).

67. Saab S, Kullar R, Khalil H, Gounder P. Cost-Effectiveness of Universal Hepatitis C

Screening in Pregnant Women: A Systematic Review. J Clin Gastroenterol 2020 (in

press).

Saab 52

EDITORIALS

1. Saab S. Transmission of hepatitis (invited commentary). In: Rickman LS, Jackson M,

eds. Reviews and comments at a glance. AJIC 1996;24:472-473.

2. Saab S. Historical perspective on pulmonary tuberculosis (invited commentary). In:

Rickman LS, Jackson M, eds. Reviews and comments at a glance. AJIC 1997;25:65-66.

3. Saab S, Yee HF Jr. Hepatorenal syndrome: a treatable process? Adv Gastroenterol

Hepatol Clin Nutr 1998;3:208-213.

4. Saab S, Martin P. Hemolytic anemia and the treatment of chronic hepatitis C (invited

commentary). J Clin Gastroenterol 1999;28:289-290.

5. Saab S, Han SHB. Successful orthotopic liver transplantation (correspondence).

Gastroenterol 2001;120:1561-1562.

6. Saab S. Hepatitis C transmission in the hemodialysis community (invited commentary).

Am J Kid Dis 2001;37:1052-1055.

7. Wang V, Saab S. Ammonia levels and severity of hepatic encephalopathy (invited

editorial). Am J Med 2003;114:237-238.

8. Saab S. Hepatocellular carcinoma screening using alpha-fetoprotein (invited

commentary). J Evidence Based Healthcare 2004;8:221-3.

9. Saab S. Role of High ALT in the Natural History of HBeAg-Negative, HBsAg-Positive

Disease. Clinical Care Options 2009.

10. Padua D, Saab S. Cart before the Horse. Ann Intern Med 2012.

http://www.annals.org/content/156/4/279.short/reply

11. Ng V, Saab S. Can Daily Coffee Consumption Reduce Liver Disease Related Mortality?

Clin Gastroenterol Hepatol. 2013;11:1422-3.

12. Suraweera D, Saab S. Hepatitis C treatment threshold in patients with decompensated

liver disease. Hepatology. 2017;65:1789-1791.

13. Saab S. Current Treatment of Thrombocytopenia in Chronic Liver Disease.

Gastroenterology and Hepatology. 2019;15:558-561.

14. Saab S. Portal Hypertension. Clin Liver Dis. 2019 Nov;23(4):xiii-xiv. doi:

10.1016/j.cld.2019.08.001.

15. Saab S, Kullar R, Gounder P. The Need for Hepatitis C Screening in Pregnant Women.

Obstetrics & Gynecology. 2020 (in press).

16. Saab S, Kim NG, Lee EW. Practical Tips on TIPS: When to Request and When Not to

Request It. Am J Gastroenterol 2020 (in press).

EDITORIALS (IN PRESS) None

PAPERS IN PREPARATION (RESEARCH COMPLETED) None.

ABSTRACTS

POSTER PRESENTATIONS

1. Saab S, Ly D, Lin R, Rojter SE, Han S, Ghobrial RM, Busuttil RW. Cost-effectiveness

of treating hepatitis C after liver transplantation. American Association for the Study of

Liver Diseases annual meeting November 2001, Dallas, TX.



Saab 53

2. Saab S, Chang A, Comulada S, Geeverghese SK, Kunder G, Durazo F, Han, S, Kunder

G, Durazo F, Yersiz H, Ghobrial RM, Farmer DG, Goldstein LI, Busuttil RW. Outcomes

of hepatitis C and hepatitis B core antibody positive grafts in orthotopic liver

transplantation. American Transplant Congress annual meeting May 2003, Washington

DC.

3. Saab S, Wang V, Ibrahim AB, Morrisey M, Durazo F, Han S, Kunder G, Durazo F,

Yersiz H, Ghobrial RM, Farmer DG, Goldstein LI, Busuttil RW. MELD score as a

predictor of post-orthotopic liver transplantation one-year patient and graft survival.

Digestive Diseases Week annual meeting May 2003, Orlando, FL.

4. Ghobrial RM, Carmody IC, Ruiz R, Kelly BS, Farmer DG, Yersiz H, Lipshutz GS, Saab

S, Hiatt J, Busuttil RW. Post-transplantation hepatitis C recurrence is influenced by non-

viral transplant-related factors: 10 years analysis in over 300 patients. American Society

of Transplantation and the American Society of Transplant Surgeons annual meeting.

May 2005, Seattle, WA.

5. Biggins S, Kim WR, Saab S, Balan V, Schiano T, Benson J, Therneau T, Kremers W,

Wiesner R, Kamath P, Terrault N. MELDS: Incorporation of the serum sodium

concentration into MELD: An evidence-based proposal. American Society of

Transplantation and the American Society of Transplant Surgeons annual meeting. May

2005, Seattle, WA.

6. Terrault N, Shiffman M, Lok A, Saab S, Gillespie B, Seeff LB, and the A2ALL Study

Group. Transplant center experience explains differences in the risk of graft failure

between hepatitis C (HCV)-infected reciepients of living donor (LDLT) and deceased

donor (DDLT) liver transplant recipients. American Association for the Study of Liver

Disease Annual Meeting. November 2005, San Francisco, CA.

7. Saab S, Hernandez JC, Chi AC, Tong. Spontaneous Bacterial Peritonitis Prophylaxis

Improves Morbidity and Mortality: A Meta-Analysis. Digestive Diseases Week annual

meeting May 2008, San Diego, CA.

8. Saab S, Yeganeh M, Nguyen K, Durazo F, Han S, Yersiz H, Farmer DG, Goldstein LI,

Tong MJ, Busuttil RW. Recurrence of Hepatocellular Carcinoma and Hepatitis B

Reinfection in HBsAg Positive Patients after Liver Transplantation. ILTS, July 2008

New York, NY.

9. Everson G, Terrault N, Lok AS, Brown RS, Saab S, Shiffman ML, Al-Osaimi AM,

Kulik LM, Gillespie BW, Everhart JE. Interim analysis of a controlled trial of pre-

transplant peginteferon alfa-2B/ribavirin (PEG/RBV) to prevent recurrent hepatitis C

virus (HCV) infection after liver transplantation (LT) in the adult-to-adult liver

transplantation (A2ALL) study. American Association for the Study of Liver Disease

Annual Meeting. November 2009, Boston, MA.

10. Levitsky J,. Norvell J, Watt KD, Curry MP, Tewani SK, McCashland TM, Shaked A,

Hoteit MA, Chi AC, Saab S, Tien A, Fiel MD, Schiano TD. Immunological Graft

Dysfunction Occurring During Pegylated Interferon Therapy for Recurrent Hepatitis C

Post Liver Transplantation.

11. McCombs J, Matsuda T, Tonhu-Mihara I, Saab S, Hines P, L’Italian G, Juday T, Yuan

Y. Impact of Treatment on Long-Term Morbidity and Mortality in Chronic Hepatitis C

Patients Receiving Care Through the U.S. Veterans Health Administration. American

Association for the Study of Liver Diseases annual meeting November 2013,

Washington, DC.

12. Sundaram V, May FP, Manne V, Saab S. Effects of Clostridium difficile Infection in

Patients with Alcoholic Hepatitis. EASL April 2014, London, Great Britain.

Saab 54

13. Saab S, Gordon SC, Park H, Ahmed A, Younossi ZM. A Decision Analytic Markov

Model to Evaluate the Health Outcomes for Sofosbuvir for Previously Untreated Patients

and Those Without Treatment Options with Chronic Hepatitis C Virus. Plenary Session.

Digestive Diseases Week annual meeting May 2014, Chicago, IL.

14. Saab S, Gordon SC, Park H, Ahmed A, Younossi ZM. A decision analytic Markov

model to evaluate the health outcomes of sofosbuvir for previously untreated patients and

those without treatment options with chronic hepatitis c virus. AASLD Plenary Session I.

Digestive Diseases Week. May 2014. Chicago, IL.

15. Agarwa K, Gane E, Forns X, Mann M, Saab S, Colombo M, Younossi, Terrault N. The

cost-effectiveness of sofosbuvir treatment pre-transplant to prevent HCV recurrence post-

transplant. ILTS June 2014, London, Great Britain.

16. Yanny B, Konyn P, Najarian L, Mitry A, Mikhail M, Saab S. Approaches to Hepatitis B

Vaccination Nonresponse. American Association for the Study of Liver Diseases Annual

Meeting. November 2018. San Francisco, CA 2018. Abstract 216.

POSTER PRESENTATIONS

1. Saab S, Martin P, Han S, Ghobrial RM, Markmann JF, Farmer DG, Drazan K, Seu P,

Goss JA, Busuttil RW. Coinfection of hepatitis B and C increases the risk of developing

hepatocellular carcinoma. American Association for the Study of Liver Diseases annual

meeting November 1998, Chicago, IL.

2. Bedford R, Saab S, Soliman GY, Han S, Ghobrial RM, Farmer DG, Martin P, Busuttil

RW. Nasobiliary drainage is the treatment of choice for biliary leakage following

orthotopic liver transplantation. American Gastroenterology Association annual meeting

May 1999, Orlando, FL.

3. Saab S, Soliman GY, Han SH, Martin P. Female patients over 50 years of age are at

increased risk of developing hepatocellular carcinoma with cirrhosis due to HCV.

American Gastroenterology Association annual meeting May 1999, Orlando, FL.

4. Saab S, Soliman GY, Han SH, Martin P. Hepatitis A seroprevelance in patients with

cirrhosis due to hepatitis C. American Association for the Study of Liver Diseases annual

meeting November 1999, Dallas, TX.

5. Saab S, Langfield D, Gitnick G, Yee HF Jr. Hepatitis C prevalence and incidence in

dialysis patients. American Association for the Study of Liver Diseases annual meeting

November 1999, Dallas, TX.

6. Saab S, Soliman GY, Han SH, Martin P, Ghobrial RM, Farmer D, Busuttil RW, Lassman

CR. Alpha-1 antitrypsin deficiency is an under-recognized cause of decompensated liver

disease in patients undergoing orthotopic liver transplantation. American Association for

the study of Liver Diseases annual meeting November 1999, Dallas, TX.

7. Saab S, Thigman M, Yee HF Jr. Endothelin-1 mediates stellate cell contractility through

the endothelin-A receptor. American Association for the Study of Liver Diseases annual

meeting November 1999, Dallas, TX.

8. Saab S, Martin P, Yee HF Jr. Serology testing prior to hepatitis A vaccination in high

risk groups. American Association for the Study of Liver Diseases annual meeting

November 1999, Dallas, TX.

9. Saab S, Hurwitz EL, Soliman GY, Han SH, Martin P, Farmer DG, Ghobrial RM,

Busuttil RW. Asian patients and patients over 50 years of age are at increased risk of

developing hepatocellular carcinoma with cirrhosis due to hepatitis C. American

Association for the Study of Liver Diseases annual meeting November 1999, Dallas, TX.

Saab 55

10. Saab S, Martin P, Ly D, Langfield D, Brezina M ,Gitnick G, Yee HF Jr. Viral hepatitis

is an infrequent cause of elevated alanine aminotransferase levels in hemodialysis

patients. American Gastroenterology Association annual meeting May 2000, San Diego,

CA.

11. Saab S, Martin P, Ly D, Langfield D, Brezina M, Gitnick G, Yee HF Jr. De novo

hepatitis B and C infection s can occur in the absence of alanine aminotransferase

elevations in dialysis patients. American Gastroenterology Association annual meeting

May 2000, San Diego, CA.

12. Saab S, Martin P, Ly D, Brezina M, Gitnick G, Yee HF Jr. Hepatitis C antibody based

testing is the preferred strategy for hepatitis C screening in hemodialysis patients.

American Association for the Study of Liver Diseases annual meeting October 2000,

Dallas, TX.

13. Ly D, Saab S, Martin P, Brezina M, Gitnick G, Yee HF Jr. Hepatitis B immunization

causes detectable hepatitis B surface antigen in hemodialysis patients. American

Association for the Study of Liver Diseases annual meeting October 2000, Dallas, TX.

14. Shimoda M, Saab S, Soliman GY, Han S, Ghobrial RM, Farmer DG, Bedford RA,

Goldstein LI, Martin P, Busuttil RW. A cost analysis of biliary anastomosis with or

without T-tube after orthotopic liver transplantation. American Association for the Study

of Liver Diseases annual meeting October 2000, Dallas, TX.

15. Weston S, Saab S, Ly D, Brezina M, Yee HF Jr, Gitnick G, Han S. A cost-effective

decision analysis model comparing two strategies for hepatitis B immunity in the

hemodialysis community. American Gastroenterology Association annual meeting May

2001, Atlanta, GA.

16. Ghobrial RM, Farmer DG, Stedman R, Yersiz H, Lassman C, Danino N, Collisson E,

Han S, Saab S, Busuttil RW. Adverse effects of HCV recurrence in over five hundred

liver transplantations. The American Society of Transplantation and the American

Society of Transplant Surgeons annual meeting May 2001, Chicago, IL.

17. Shimoda M, Saab S, Morrisey M, Ghobrial MR, Farmer DG, Han S, Bedford RA,

Goldstein LI, Martin P, Busuttil RW. A cost-effectiveness analysis of biliary

anastomosis with or without t-tube after orthotopic liver transplantation. The American

Society of Transplantation and the American Society of Transplant Surgeons annual

meeting May 2001, Chicago, IL.

18. Ghobrial RM, Amersi F, Farmer DG, Chen P, Anselmo DM, Baquerizo A, Geeverghese

S, Hisitake G, Renz J, Han S, Saab S, Busuttil RW. Rapid and severe early HCV

recurrence following adult living donor liver transplantation. The American Society of

Transplantation and the American Society of Transplant Surgeons annual meeting April

2002, Washington, DC.

19. Ghobrial RM, Gornbein J, Anselmo D, Steadman R, Danino N, Yersiz H, Saab S,

Busuttil RW. Pretransplantation model to predict posttransplant survival in OLT for

HCV. The American Society of Transplantation and the American Society of Transplant

Surgeons annual meeting April 2002, Washington, DC.

20. Saab S, Ghobrial RM, Han S, Chen P, Farmer D, Danino N, Yersiz H, Goldstein LI,

Bususttil RW. Hepatitis C infected grafts may be used in orthotopic liver transplantation:

A matched analysis. The American Society of Transplantation and the American Society

of Transplant Surgeons annual meeting April 2002, Washington, DC.

21. Derosa V, Nieto J, Saab S. Decision anayltic model comparing strategies for primary

prophylaxis of variceal bleeding in patients with hepatic cirrhosis. American

Gastroenterology Association annual meeting May 2002, San Francisco, CA.

Saab 56

22. Kanwal F, Chen D, Saab S, Durazo F, Busuttil RW, Han S. Predictors of poet-liver

transplant altered metal status of unclear etiology. American Association for the Study of

Liver Diseases annual meeting November 2002, Boston, MA.

23. Vogel W, Ferenci P, Fontana R, Arbor A, Saab S, LaBrecque D, Pappas SC, Sidhu RK,

Harb GE. Peginterferon alfa-2A (40KD) (Pegasys ®) in liver transplant recipients with

established recurrent hepatitis C; interim results of an ongoing randomized multicenter

trial. American Association for the Study of Liver Diseases annual meeting November

2002, Boston, MA.

24. Saab S, DeRosa VP, Nieto J, Durazo F, Han S, Roth B. Costs and clinical outcomes of

primary prophylaxis of variceal bleeding in cirrhotics: A decision analytic model.

American Association for the Study of Liver Diseases annual meeting November 2002,

Boston, MA.

25. Nieto J, Saab S. Medical versus surgical and radiological treatment of refractory ascites:

A meta-analysis of randomized controlled trials. American Association for the Study of

Liver Diseases annual meeting November 2002, Boston, MA.

26. Karsan HA, Lee C, Dong PR, Durazo F, Saab S, Han S. Do transjugular intrahepatic

postosystemic shuts (TIPS) for refractory ascites really work? American Association for

the Study of Liver Diseases annual meeting November 2002, Boston, MA.

27. Saab S, Hu RR, Ibrahim AB, Goldstein LI, Kunder G, Durazo F, Han S, Yersiz H,

Ghobrial R, Farmer DG, Busuttil RW, Lassman C. Discordance between alanine

aminotransferase and liver histology in liver transplant recipients treated with ribivarin

monotherapy for recurrent hepatitis C virus. American Association for the Study of Liver

Diseases annual meeting November 2002, Boston, MA.

28. Saab S, Ghobrial RM, Ibrahim AB, Han S, Chen P, Farmer D, Durazo F, Yersiz H,

Goldstein LI, Busuttil RW. Hepatitis C positive grafts may be used in orthotopic liver

transplantation: A matched analysis. American Association for the Study of Liver

Diseases annual meeting November 2002, Boston, MA.

29. Saab S, Ly D, Nieto J, Kanwal F, Durazo F, Han S, Busuttil. Hepatocellular carcinoma

surveillance in patients awaiting liver transplantation can be cost-effective. American

Association for the Study of Liver Diseases annual meeting November 2002, Boston,

MA.

30. Saab S, Wang VS, Ibrahim AB, Durazo F, Han S, Farmer DG, Ghobrial RM, Yersiz H,

Morrisey M, Godstein LI, Busuttil RW. MELD score can predict post-orthotopic liver

transplantation one-year patient and graft survival. American Gastroenterology

Association annual meeting May 2003, Orlando, FL.

31. Saab S, Wang V, Ibrahim AB, Durazo F. Han S, Farmer DG, Ghobrial RM, Yersiz H,

Goldstein LI, Busuttil RW. MELD score can predict port-orthotopic liver transplantation

one-year patient and graft survival. The American Society of Transplantation and the

American Society of Transplant Surgeons annual meeting May 2003, Washington, DC.

32. Saab S, Chang A, Comulada S, Geeverghese SK, Anselmo DM, Ghobrial RM, Kunder

G, Durazo F, Han S, Farmer DG, Yersiz H, Goldstein LI, Busuttil RW. Outcomes of

hepatitis C and hepatitis B core antibody positive grafts in orthotopic liver

transplantation. The American Society of Transplantation and the American Society of

Transplant Surgeons annual meeting May 2003, Washington, DC.

33. Ghobrial RM, Fondevila C, Limanond P, Raman SS, Lassman C, Sayre J, Saab S, Lu D,

Busuttil RW. Utility of liver biopsy and computed tomography in evaluation of

candidates for living donor liver transplantation. The American Society of

Saab 57

Transplantation and the American Society of Transplant Surgeons annual meeting May

2003, Washington, DC.

34. Ghobrial RM, Huang Y, Farmer DG, Carmody IC, Gornbein J, Steadman R, Saab S,

Goldstein L, Yersiz H, Durazo F, Han S, Tang L, Busuttil RW. Posttransplant hepatitis C

recurrence is influenced by non-viral transplant related factors: Ten-year analysis in over

300 patients. The American Society of Transplantation and the American Society of

Transplant Surgeons annual meeting May 2003, Washington, DC.

35. Tsuchiya M, Saab S, Farmer DG, Saggi B, Gordon, SA, Hisatake GM, Lenz JF, Ghobrial

MR, Yersis H, Busuttil RW. Liver transplantation for obesity related cryptogenic

cirrhosis. How does weight affect post-operative survival? American Association for the

Study of Liver Diseases annual meeting October 2003, Boston, MA.

36. Ghobrial RM, Carmody I, Huang YM, Saab S, Gornbein JA, Steadman R, Han S,

Durazo Farmer DG, Yersiz H, Holt CD, Goldstein L, Busuttil RW. Early hepatitis C

recurrence following liver transplantation is influenced by operative and per-transplant

variables. American Association for the Study of Liver Diseases annual meeting October

2003, Boston, MA.

37. Kamal M, Lassman CR, Ghobrial RM, Saab S, Marks K, Busuttil RW. Histologic

findings in potential living liver donor biopsies. American Association for the Study of

Liver Diseases annual meeting October 2003, Boston, MA.

38. Nieto J, Saab S. Transjugular intrahepatic portosystemic shunt versus paracentesis in the

treatment of refractory ascites: A meta-analysis of randomized trials. American

Gastroenterology Association annual meeting May 2004, New Orleans, LA.

39. Fondevila C, Ghobrial RM, Bombuy E, Gordon S, Fuster J, Saggi B, Charco R, Saab S,

Busuttil RW. Definition of donor surgical variants associated with reduced graft

outcomes following ALDLT. The American Society of Transplantation and the

American Society of Transplant Surgeons annual meeting May 2004, Boston, MA.

40. Saab S, Niho H, Comulada S, Ghobrial RM, Hiatt J, Durazo F, Han S, Farmer DG, Holt

C, Yersiz H, Goldstein LI, Busuttil RW. Risk factors for death in recipients with

recurrent hepatitis C cirrhosis. The American Society of Transplantation and the

American Society of Transplant Surgeons annual meeting May 2004, Boston, MA.

41. Ghobrial RM, Holt CD, Sievers TM, Saab S, Artinian L, McDiarmid SV, Busuttil RW.

Mycophenolate mofetil in liver transplantation for hepatitis C: Effect on recurrence and

pharmacokinetics. The American Society of Transplantation and the American Society

of Transplant Surgeons annual meeting May 2005, Seattle, WA.

42. Ghobrial RM, Holt CD, Sievers TM, Saab S, Artinian L, McDiarmid SV, Busuttil RW.

Mycophenolate mofetil: Pharmacokinetics and effect on hepatitis C recurrence n liver

transplantation. The American Society of Transplantation and the American Society of

Transplant Surgeons annual meeting May 2005, Seattle, WA.

43. Saab S, Ibrahim AB, Shpaner A, Brito I, Fraser K, Marehbian J, Durazo F, Han S,

Farmer DG, Ghobrial RM, Holt C, Yersiz H, Goldstein LI, Tong MJ, Busuttil RW.

Prevalence and risk factors for diabetes mellitus in liver transplantation recipients. The

American Society of Transplantation and the American Society of Transplant Surgeons

annual meeting May 2005, Seattle, WA.

44. Saab S, Landaverde C, Ibrahim A, Durazo F, Han S, Farmer DG, Ghobrial M, Holt C,

Yersiz H, Goldstein L, Lipshutz G, Tong MJ, Busuttil RW. Predictors of mortality and

MELD scores changes while waiting for liver transplantation. The American Society of

Transplantation and the American Society of Transplant Surgeons annual meeting May

Saab 58

2004, Boston, MA. The American Society of Transplantation and the American Society

of Transplant Surgeons annual meeting. May 2005, Seattle, WA.

45. Saab S, Nguyen S, Ibrahim A, Tong M. Management of Cirrhosis in Southern

California. American Gastroenterology Association annual meeting May 2005.

46. Kim A, Bouajram R, Dorn A, Saab S. The treatment of chronic hepatitis C in HIV-

infected patients: a meta-analysis. American Gastroenterology Association annual

meeting May 2006.

47. Trotter JF, Blei AT, Everhart JE, Lok AS, Wisniewski KA, Freise CE, Saab S, Campsen

PJ, Study Group and the A2ALL. Outcomes of Donors and Recipients Following Living

Donor Liver Transplantation for Acute Liver Failure. American Association for the Study

of Liver Diseases annual meeting October 2006, Boston, MA.

48. Saab S, Wiese C, Ibrahim AB, Durazo F, Han S, Yersiz H, Farmer DG, Ghobrial RM,

Goldstein LI, Tong MJ, Busuttil RW. Employment and quality of life in liver transplant

recipients. American Association for the Study of Liver Diseases annual meeting

October 2006, Boston, MA.

49. Martyak LA, Taqavi E, Saab S. Lamivudine Prophylaxis for Hepatitis B Reactivation in

Patients Undergoing Cytotoxic Chemotherapy: A Systematic Review. American

Gastroenterology Association annual meeting May 2007.

50. Saab S, Dong M, Joseph T, Tong M. Hepatitis B prophylaxis in patients undergoing

chemotherapy for lymphoma: A decision analysis model. American Gastroenterology

Association annual meeting May 2007.

51. Saab S, Ibrahim AB, Surti B, Durazo F, Han S, Yersiz H, Farmer DG, Ghobrial RM,

Goldstein LI, Tong MJ, Busuttil RW Pre-transplant variables associated with qualify of

life in liver transplant recipients. American Association for the Study of Liver Diseases

annual meeting October 2007, Boston, MA.

52. Tan J, Joseph T, Saab S. Treating Hepatitis C in the Prison Population is Cost-Saving.

American Gastroenterology Association annual meeting May 2008, San Diego, CA.

53. Bownik H, Saab S. Autoimmune Hepatitis-Primary Biliary Cirrhosis Overlap Syndrome:

An Example Of Sequential Development. Presented at the SGIM National Meeting. May

2009, Miami, Florida. Winner of Outstanding Clinical Vignette.

54. Saab S, Hunt D, Stone MA, McClune A, Tong MJ. Timing of Hepatitis C Antiviral

Therapy Pre and Post Liver Transplantation: A Decision Analysis Model. American

Association for the Study of Liver Diseases annual meeting October 2009, Boston, MA.

55. Saab S, McTigue M, Finn R, Busuttil RW. Sorafenib Prophylaxis is Effective in

Preventing Hepatocellular Carcinoma Recurrence in Liver Transplant Recipients.

International Liver Transplantation Society annual meeting. June 2010, Hong Kong,

China

56. McCombs J, Yuan Y, Shin J, Saab S. Chronic Hepatitis C Infections and the Risk of

Depression and Other Adverse Events. American Association for the Study of Liver

Diseases annual meeting October 2010, Boston, MA

57. McCombs J, Yuan Y, Yu Y, Saab S. A longitudinal database study of economic

consequences of chronic hepatitis C virus (HCV) infections in U.S. ISPOR 16th Annual

International Meeting May 2011, Baltimore, MD.

58. McCombs J, Yuan Y, Yu Y, Saab S. Real-World Evaluation of the Economic Impact of

Duration of Drug Therapy in the Treatment of Hepatitis C Virus (HCV). American

Gastroenterology Association annual meeting May 2011, Chicago, IL. CA.

Saab 59

59. McCombs J, Yuan Y, Yu Y, Saab S. Impact of Newly Diagnosed Hepatitis C Infections

on Health care Costs American Gastroenterology Association annual meeting May 2011,

Chicago, IL. CA. (Poster of Distinction)

60. Younossi ZM, Gordon SC, Saab S, Ahmed A, Brogan A, Cure S. A Decision Analytic

Markov Model to Evaluate the Health Outcomes of Sofosbuvir for Previously Untreated

Patients with Chronic Hepatitis C Virus Genotype 1 Infection. American Association for

the Study of Liver Diseases annual meeting November 2013, Washington, DC.

61. Younossi ZM, Saab S, Gordon SC, Ahmed A, Brogan A, Guerra I. Evaluation of the

Long-Term Health Outcomes Associated with Earlier Versus Later Initiation of

Treatment in Previously Untreated Patients with Chronic Hepatitis C Virus Genotype 1

Infection. American Association for the Study of Liver Diseases annual meeting

November 2013, Washington, DC.

62. McCombs J, Matsuda T, Tonhu-Mihara I, Saab S, Hines P, L’Italian G, Juday T, Yuan

Y. Using Laboratory Data to Predict Long-Term Morbidity and Mortality in Chronic

Hepatitis C Patients in the U.S. Veterans Health Administration. American Association

for the Study of Liver Diseases annual meeting November 2013, Washington, DC.

(Poster of Distinction)

63. Saab S, Manne V, Bau S, Reynolds JA, Allen R, Goldstein L, Durazo F, El-Kabany M,

Han S, Busuttil RW. Boceprevir in Liver Transplant Recipients. EASL April 2014,

London, Great Britain.

64. Stepanova M, Hunt SL, Saab S, Frost S, Jeffers T, Younossi ZM. Outcomes of liver

transplantation in the United States: what has changed over the last 25 years? Digestive

Diseases Week. May 2014. Chicago, IL.

65. Choi G, Lee K, Wu C, Saab S. Renal transplantation threshold in patients with hepatitis

C liver fibrosis and cirrhosis: a decision analysis model. Digestive Diseases Week. May

2014. Chicago, IL.

66. Zhou K, Ferguson J, Elashoff D, Saab S. Treating chronic hepatitis C infection in the

elderly: estimated impact on life expectancy. Digestive Diseases Week. May 2014.

Chicago, IL.

67. Saab S, Manne V, Akhtar E. Cirrhosis regression in hepatitis C patients with sustained

virologic response after anti-viral therapy: a meta-analysis. Digestive Diseases Week.

May 2014. Chicago, IL.

68. Sundaram V, May FP, Manne V, Saab S. Clostridium difficile infection and acute

alcoholic hepatitis: the associated risk, mortality, and health care utilization. Digestive

Diseases Week. May 2014. Chicago, IL.

69. Gordon SC, Ahmed A, Saab S, Younossi Z. Evaluation of the Long-Term Health

Outcomes of Ledipasvir/Sofosbuvir (LDV/SOF) and Sofosbuvir-based Regimens for

Patients with Chronic Hepatitis C (CHC) And Liver Cirrhosis Across Genotypes 1 to 4

(GT 1-4): Results from a Decision-Analytic Markov Model. American Association for

the Study of Liver Diseases Annual Meeting November 2014, Boston, MA.

70. Ahmed A, Gordon SC, Saab S, Younossi Z. Evaluation of Health Outcomes for

Ledipasvir/Sofosbuvir in Early vs. Delaed Treatment According to Fibrosis Stage of

Patients with Chronic Hepatitis C Virus (HCV) Genotype 1 Infection: Results from a

Decision-Analytic Markov Model. American Association for the Study of Liver Diseases

Annual Meeting November 2014, Boston, MA.

71. Younossi Z, Saab S, Ahmed A, Gordon SC. A Decision-Analytic Markov Model to

Evaluate the Health Outcomes of Ledipasvir/Sofosbuvir (LDV/SOF) for Patients with

Saab 60

Chronic Hepatitis C (HCV) Genotype 1 (GT1) Infection. American Association for the

Study of Liver Diseases Annual Meeting November 2014, Boston, MA.

72. Johnson SJ, Parise H, Virabhak S, Juday TR, Samp JC, Marx SE, Saab S. SVR Reduces

Morbidity/Deaths by 5-10 Fold - Abbvie Analysis - Percent of Subjects Experiencing

Liver Morbidity Over a Lifetime Horizon with AbbVie 3D (Abt-

50/Ritonavir/Ombitasvirand Dasabuvir) Versus No treatment. European Association for

the Study of the Liver. April 2015, Vienna, Austria.

73. Johnson SJ, Samp JC, Juday TR, Marx SE, Parisé H, Virabhak C, Saab S. Reduction in

Annual Medical Costs with Early Treatment of HCV Using Abbvie 3D (AbT-

450/Ritonavir/Ombitasvir and Dasabuvir) ± Ribavirin in the United States. European

Association for the Study of the Liver. April 2015, Vienna, Austria.

74. Johnson S, Parise H, Sanchez Gonzalez Y, Wang A, S Virabhak S, Juday T, Saab S. The

Value of Survival Benefits from Treating Hepatitis C at Different Fibrosis Stages with

All-Oral, Interferon-Free Therapy Relative to 'Watchful Waiting'. European Association

for the Study of the Liver. April 2015, Vienna, Austria.

75. Johnson SJ, Juday TR, Samp JC, Marx SE, Parisé H, Virabhak S, Saab S. Cost-

Effectiveness of Treating Different Stages of Genotype 1 Hepatitis C Virus (GT1-HCV)

With Viekira Pak (Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir) ± Ribavirin

Compared to No Treatment in the United States. European Association for the Study of

the Liver. April 2015, Vienna, Austria.

76. Lui A, Perumpail RB, Jayasekera CR, Tummala S, Saab S, Younossi ZM, Wong RJ,

Ahmed A. HCV Infection in Aging Baby Boomers is an Independent Predictor of Poor

Outcome in Liver Transplant Recipients: An Analysis of the UNOS Database. American

Association for the Study of Liver Diseases Annual Meeting November 2015, San

Francisco, CA.

77. Younossi ZM, Park H, Dieterich D, Saab S, Ahmed A, Gordon SC. Quality-Adjusted

Cost of Care for Treatment Naïve (TN) Patients with Genotype 1 (GT1) Chronic

Hepatitis C (CH-C): An Assessment of Innovation Cost of Drug Regimens versus the

Value of Health Gains to the Society. American Association for the Study of Liver

Diseases Annual Meeting November 2015, San Francisco, CA.

78. Saab S, Virabhak S, Johnson SJ, Parisé H, Sanchez Y, Wang A, Juday TR. Lifetime risks

of liver morbidity and mortality in patients with chronic genotype (GT) 1 hepatitis c virus

(HCV) and HIV c coinfection treated with 3D±R (ombitasvir/paritaprevir/ritonavir,

dasabuvir ± ribavirin) vs other standards of care in the US. American Association for the

Study of Liver Diseases Annual Meeting November 2015, San Francisco, CA.

79. Szabo AM, Walker DR, Juday TR, Lane S, Saab S. Patient Reasons for Initiating or

Delaying Hepatitis C Virus (HCV) Treatment and Physician Reasons for Selecting an

HCV Treatment: A prospective Observational Study. American Association for the Study

of Liver Diseases Annual Meeting November 2015, San Francisco, CA.

80. Virabhak S, Johnson SJ, Parisé H, Juday TR, Wang A, Sanchez Y, Saab S. Cost-

effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir +/- ribavirin (3D±R) in

patients with genotype (GT) 1 chronic hepatitis C virus (HCV) and human

immunodeficiency virus (HIV) coinfection compared with other standards of care in the

US. American Association for the Study of Liver Diseases Annual Meeting November

2015, San Francisco, CA.

81. Saab S, Huber C, Wang A, Sanchez Y, Juday TR. Lifetime risks of liver morbidity and

mortality in patients with recurrent genotype 1 hepatitis C virus infection post-liver

transplantation treated with ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin

Saab 61

(3D+R) vs former standards of care. American Association for the Study of Liver


82. Szabo SM, Walker DR, Juday TR, Lane S, Levy A, Saab S. Patient Expectations of the

Impact on Quality of Live of Hepatitis C Treatment. American Association for the Study

of Liver Diseases Annual Meeting November 2015, San Francisco, CA.

83. Saab S, Sanchez Y, Huber C, Wang A, Juday TR. The cost-effectiveness of

ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin (3D+R) in patients with liver

transplantation after genotype 1 hepatitis C virus infection. American Association for the

Study of Liver Diseases Annual Meeting November 2015, San Francisco, CA.

84. Patel AA, Shah O, Saab S, Sundaram V. The burden of osteoporotic hip and spine

fractures in elderly patients with cirrhosis. American Association for the Study of Liver


85. Younossi ZM, Park H, Dieterich D, Saab S, Ahmed A, Gordon SC. The Value of Cure

Associated with Treating Treatment-naïve (TN) Chronic Hepatitis C (CH-C) Genotype 1

(GT1): Are the New Oral Regimens a Good Value to Society? American Association for

the Study of Liver Diseases Annual Meeting November 2015, San Francisco, CA.

86. Perumpail RB, Liu A, Jayasekera CR, Marcus JH, Tummala S, Saab S, Younossi ZM.

An evidence-Based Algorithm to Optimize Patient Selection among Class III Obese

Liver Transplant Waitlist Registrants. American Association for the Study of Liver


87. Saab S, Gonzalez ST, Perumpail RB, Cholankeril G, Ahmed A, Younossi ZM. Cost

Effectiveness Analysis of Pre vs. Post LT Treatment with All Oral Direct Acting

Antivirals in Hepatitis C Patients with Decompensated Cirrhosis in the US. American

Association for the Study of Liver Diseases Annual Meeting November 2016. Boston,

MA.848. Presidential Poster of Distinction

88. Ahmed A, Saab S, Gordon SC, Dieterich DT, Wong RJ, Brown KA, Kugelmas M,

Younossi ZM. A Decision Analytic Markov Model to Evaluate the Health Outcomes of

Sofosbuvir/Velpatasvir for Patients with Chronic Hepatitis C Virus Genotypes 1 to 6 and

Decompensated Cirrhosis in the US. American Association for the Study of Liver

Diseases Annual Meeting November 2016. Boston, MA.850. Presidential Poster of

Distinction

89. Younossi ZM, Gordon SC, Dieterich DT, Wong R, Brown KA, Kugelmas M, Saab S,

Ahmed A. A Decision Analytic Markov Model to Evaluate the Health Outcomes of

Sofosbuvir/Velpatasvir for Patients with Chronic Hepatitis C Virus Genotype 1 infection

in the US. American Association for the Study of Liver Diseases Annual Meeting

November 2016. Boston, MA.856. Presidential Poster of Distinction

90. Gordon SC, Ahmed A, Kugelmas M, Dieterich DT, Wong R, Brown KA, Saab S,

Younossi ZM. A Decision Analytic Markov Model to Evaluate the Health Outcomes of

Sofosbuvir/Velpatasvir for Patients with Chronic Hepatitis C Virus Genotypes 2 and 3

Infection in the US. American Association for the Study of Liver Diseases Annual

Meeting November 2016. Boston, MA.858. Presidential Poster of Distinction.

91. Cholankeril G, Perumpail RB, Yoo ER, Hu M, Ahmed A, Saab S, Gonzalez SA,

Beckerman R. Direct-Acting Antiviral Therapy and Purgatory MELD: Fact or Fiction?

American Association for the Study of Liver Diseases Annual Meeting November 2016.

Boston, MA.859.

92. Tavakoli H, Robinson A, Liu B, Bhuket T, Younossi ZM, Saab S, Ahmed A, Wong RJ.

Patients with Nonalcoholic Steatohepatitis Cirrhosis Are Significantly Less Likely to

Receive Appropriate Screening for Hepatocellular Carcinoma Compared to Patients with

Saab 62

Chronic Hepatitis C Virus Cirrhosis. American Association for the Study of Liver

Diseases Annual Meeting November 2016. Boston, MA.1299.

93. Nguyen K, Jimenez M, Moghadam N, Wu C, Farid A, Grotts J, Elashoff D, Choi G,

Durazo FA, El-Kabany MM, Han SB, Saab S. Decrease of Alpha-Fetoprotein in Patients

with Cirrhosis Treated with Direct Acting Agents. Gastroenterology Updates in IBD &

Liver Disease, February 19 – 22, 2017, Maui, HI

94. Younossi Z, Stepanova M, Saab S, Hoyle KE, Cable R, Mishra A, Clement SC, Hunt SL.

Patients with Non-Alcoholic Steatohepatitis are at High Risk of Developing Post-

Transplant Diabetes. American Association for the Study of Liver Diseases Annual

Meeting November 2014, Boston, MA.

95. Nguyen K, Weber A, Choi G, Durazo FA, El-Kabany MM, Kang S, Saab S, Han SB.

Minimal monitoring in treating Hepatitis C with Direct Acting Antivirals.

Gastroenterology Updates in IBD & Liver Disease, February 19 – 22, 2017, Maui, HI

96. Nguyen K, Konyn P, Choi G, Durazo FA, Han SB, Ramirez S, Saab S, El-Kabany MM.

Lower sustained virologic response in patients with hepatocellular carcinoma treated for

hepatitis C with direct acting antivirals. Annual Meeting European Association for the

Study of Liver Diseases, April 19 – 23, 2017, Amsterdam, The Netherlands

97. Younossi ZM, Stepanova M, de Avila L, Ahmed A, Wong RJ, Saab S, Kowdley KV,

Brown KA, Kugelmas M, Racila A. Liver Transplant (LT) Candidates with Primary

Biliary Cholangitis (PBC) Experience Higher Wait List Mortality: Data from the

Scientific Registry of Transplant Recipients (SRTR). American Association for the Study

of Liver Diseases Annual Meeting October 2017, Washington DC.

98. Nguyen KT, Konyn P, Darwish T, Choi G, Durazo FA, Han SH, Ramirez S, Saab S, El-

Kabany MM. Lower sustained virologic response in patients with hepatocellular

carcinoma treated for hepatitis C with direct acting antivirals. American Association for

the Study of Liver Diseases Annual Meeting October 2017, Washington DC.

99. Gordon SC, Ahmed A, Saab S, Dieterich DT, Wong RJ, Kugelmas M, Brown KA,

Younossi ZM. Health Outcomes Associated with Sofosbuvir-based Single-Tablet

Regimens for Initial and Re-treatment of Chronic Hepatitis C in the US. American

Association for the Study of Liver Diseases Annual Meeting October 2017, Washington

DC.

100. Saab S, Parisé H, Virabhak S, Johnson S, Pinsky B, Sanchez Y. Pan-genotypic hepatitis

C treatment with glecaprevir/pibrentasvir achieves greatest improvements in quality-

adjusted life-years and lifetime risk reductions in liver-related morbidity and mortality vs

standards of care: a cost-utility analysis. American Association for the Study of Liver

Diseases Annual Meeting October 2017, Washington DC.

101. Aby E, Phan J, Saab S. The Impact of Inadequate HCC Screening in patients with NASH

Cirrhosis on Tumor Size. American Association for the Study of Liver Diseases Annual

Meeting October 2017, Washington DC.

102. Saab S, Alkhouri N, Allen L, Aggarwal K, Vredenburg M, Tian W, Terrault N. Efficacy

of Avatrombopag Compared with Placebo Across Various Mean Baseline Platelet Count

Subgroups- Pooled Data from 2 Phase III Studies. European Association for the Study of

the Liver Annual Meeting 2018, Paris, Francis.

103. Reau N, Saab S, Allen L, Aggarwal K, Vredenburg M, Kim R. Avatrombopag Decreases

Need for Platelet Transfusion in Patients with Chronic Liver Disease (CLD) and

Thrombocytopenia (TCP) Undergoing Medical Procedures with Low to High Associated

Bleeding Risks. European Association for the Study of the Liver Annual Meeting 2018,

Paris, Francis.

Saab 63

104. Yanny B, Saab S, Durazo F, Latt N, Mikhail M, Mitry A and Sahota A. Eight Week

Hepatitis C Treatment with New Direct Acting Agents Have a Better Safety Profile

While Effective in the Geriatric Population without Liver Cirrhosis and Hepatitis C

Virus-RNA <6 Million IU/Ml. American Association for the Study of Liver Diseases

Annual Meeting. November 2018. Abstract 696.

105. Patel A, Ryan G, Walling A, Chuang E, Cain C, Tran D, Gupta N, Wu T, Saab S,

Khemichian S, Sundaram V, Brook R, Wenger N. Advance Care Planning for Patients

with Decompensated Cirrhosis: Preliminary Results of a Multi-Center Qualitative Study.

American Association for the Study of Liver Diseases Annual Meeting. November 2018.

San Francisco, CA 2018. Abstract 764

106. Saab S, Saggi S, Akbar M, Choi G. Presumed Consent: A Potential Tool for Countries

Experiencing an Organ Donation Crisis. American Association for the Study of Liver

Diseases Annual Meeting. November 2018. Abstract. 1149B.

107. Reau N, Saab S. Allen LF, Aggarwal K, Vredenburg M, Kim R. Avatrombopag

Decreases Need for Platelet Transfusion in Patients with Chronic Liver Disease and

Thrombocytopenia Undergoing Medical Procedures with Low to High Associated

Bleeding Risks. Society of Interventional Radiology. Austin, TX March 23-28.

108. Wang Y, Lenhart A, Grewal J, Boutros S, Saleh F, Saab S, Yanny B. Liver

Transplantation for Alcoholic Hepatitis Offers the Best Survival Benefit: A Systematic

Review. Digestive Diseases Week. May 2020. Chicago, IL.

109. Wu E, Meneses KG, Kang S, Lee AK, Neogi S, Saab S. Marijuana Usage in Post-Liver

Transplant Recipients. Digestive Diseases Week. May 2020. Chicago, IL.

110. Winters AC, Viramontes MR, Buch A, Najarian L, Yum JJ, Yang L, Saab S. Less

Educated Patients with Hepatocellular Carcinoma are Not as Prepared for the

Survivorship Experience: Outcomes From a Survey-Based Study. Digestive Diseases

Week. May 2020. Chicago, IL.

111. Veracruz N, Hameed B, Saab S, Wong R. The Association between Nonalcoholic fatty

liver Disease and Risk of Cardiovascular Disease, stroke, and Extra-Hepatic Cancers: A

Systematic Review and Meta-Analysis. Digestive Diseases Week. May 2020. Chicago,

IL.

112. Perumpail RB, Khemichian S, Lakhoo K, Do A, Choi G, Durazo FA, EI-Kabany M,

Saab S, Busuttil RW, Han SH. Tenofovir Alafenamide for Hepatitis B Virus Prophylaxis

Post-Liver Transplantation is Associated with Improved Renal Function: A Multicenter

Real-World Experience. Digestive Diseases Week. May 2020. Chicago, IL.

Documents

PERSONAL HISTORY Work Pfleger Liver Institute Suite 214